Zusammenfassung
Die Hauptgruppe der serotonin-selektiven Antidepressiva stellen die serotonin-selektiven Rückaufnahme-Inhibitoren (Wiederaufnahmehemmer) (SSRI)dar. In deutschsprachigen Ländern derzeit verfügbare Substanzen sind>
-
Citalopram/Escitalopram
-
Fluoxetin
-
Fluvoxamin
-
Paroxetin
-
Sertralin
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Serotonin-selektive Antidepressiva(SSRI, DSA)
Pharmakologie
BAUMANN P(1996)Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 31:444–469
BAUMANN P (1998)Care of depression in the elderly: comparative pharmacokinetics of SSRIs. lilt Clin Psychopharmacol 13 1Supp1 51: S35–S43
CACCIA S (1998) Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 34: 281–302
DEVANE CL (1999) Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell Mol Neurobiol 19: 443–466.
GLEITER CH (1999) Pharmakokinetik. In: (GLEITER CH, VoLZ HP, MOLLER HJ (Hrsg) SerotoninWiederaufnahmehemmer. Wissenschaftliche Verlagsgesellschaft, Stuttgart, S 32–52
GREENE DS, BARBHAIYA RH (1997) Clinical pharmacokinetics of nefazodone. Clin Pharmacokinet 33: 260–275
HIEMKE C(1994)Paroxetin:Pharrnakokinetik und Pharmakodynamik. Fortschr Neurol Psychiat 62 [Suppl 1]: 2–8
ROTZINGER S,BOURIN M,AKIMOTO Y, Courts RT,BAKER GB (1999) Metabolism of some „second“- and „fourth”-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine. Cell Mol Neurobiol 19: 427–442
VAN HARTEN J (1995) Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet 29 [Suppl 1]: 1–9
Neurobiochemie, Wirkmechanismus
BROSEN K,SKJELBO E,RASMUSSEN BB,PUOLSEN HE,LOFT S (1993) Fluvoxamine is a potent in-hibitor of cytochrome P450 1A2. Biochern Pharmacol 45: 1211–1214
BROTrO LA,HANSON LA,GORZALKA BB (1999) Nefazodone attenuates the stress-induced facilitation of wet dog shaking behaviour but not the facilitation of sexual behaviour in female rats. Eur J Pharmacol 381: 101–104
BAKER GB,JOLLIET P (2001) Comparison of antidepressant activity in 4- and 40-week-old male mice in the forced swimming test: involvement of 5-HT1A and 5-HT1B receptors in old mice. Psychopharmacology (Berl) 153: 443–449
DAVIS R,WHITTINGTON R,BRYSON HM (1997) Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs 53: 608–636
DELINI-STULA A (1989) Animal models in the research of antidepressants and their experimental validation. Habilitation, Universität Basel
DUNCAN GE, KNAPP DJ, LITTLE KY, BREESE GR (1994) Neuroanatomical specificity and dose dependence in the time course of imipramineinduced beta adrenergic receptor down-regulation in rat brain. J Pharmacol Exp Ther 271: 1699–1704
ECKERT A, REIFF J, MÜLLER WE (1997) Pharmako-kinetische Grundlagen der Therapie mit Sertralin. Psychopharmakotherapie 7: 9–17
ECKERT A, REIFF J, MÜLLER WE (1998) Medical interactions with antidepressives. Benefits of the specific serotonin reuptake inhibitor citalopram. Med Monatsschr Pharm 21: 138–150
EIsoN AS, EISON MS, TORRENTE JR, WRIGHT RN,YOCCA FD (1990) Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 26: 311–315
HERTEL P, NoMIKOS GG, tURLO M. SVENSSON TH (1996) Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology (Berl) 124: 74–86
HERTEL P, NoslKos GG, SVENSSON TH (1997) Risperidone inhibits 5-hydroxytryptaminergic neuronal activity in the dorsal raphe nucleus by local release of 5-hydroxytryptamine. Br J Pharmacol 122: 1639–1646
HEYM J, ROE BK (1988) Pharmacology of sertra-line. J Clin Psychiatry 49 [Suppl 8]: 40–45
HYTrEL J (1994) Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 9 [Suppl 1]: 19–26
HYTTEL J, ARNT J, SANCHEZ C (1995) The pharmacology of citalopram. Contemp Pharmacother 6: 271–285
JOHN L, PERREAULT MM, TAO T, BLEW PG (1997) Serotonin syndrome associated with nefazodone and paroxetine. Ann Emerg Med 29: 287–289
KLEINLOGEL H, BURKI HR (1987) Effects of the selective 5-hydroxytryptamine uptake inhibitors paroxetine and zimeldine On EEG sleep and waking stages in the rat. Neuropsychobiology 17: 206–212
LANE R, BALDWIN D, PRESKORN SH (1995) The SSRIs: advantages, disadvantages and differences. J Psychopharmacol 9: 1–16
LEONARD BE (1993) The comparative pharmacology of new antidepressants. J Clin Psychiatry 54 [Suppl]: 3–15
LEONARD BE (1996) New approaches to the treatment of depression. J Clin Psychiatry 57 [Suppl 4]: 26–33
MARGOLESE HC, CIIOUINARD G (2000) Serotonin syndrome from addition of low-dose trazo-donc to nefazodone. Am J Psychiatry 157: 1022
MATHESON GK, KNOWLES A, GUTIIRIE D, GAGE D, WEINZAPFEL D, BLACKBOURNE J (1997) Actions of serotonergic agents on hypothalamic-pituitary-adrenal axis activity in the rat. Gen Pharmacol 29: 823–828
MEYER JH, KAPUR S, EISFELD B, BROWN GM, HOULE S, DASILVA J, WILSON AA, RAFI-TARI S, MAYBERG HS, KENNEDY SH (2001) The effect of paroxe-tine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. Am J Psychiatry 158: 78–85
MÜLLER WE (1995) Wie wirken Schlafmittel? - Sedierende Antidepressiva und Neuroleptika. ZNS im Dialog 2: 8–9
MÜLLER WE(1997)Pharmakodynamische Aspekte neuer Antidepressiva. Psychopharmakotherapie 4 [Suppl 6]: 2–7
MÜLLER WE, ECKERT A (1997) Pharmakodynamisehe Grundlagen der Therapie mit spezifischen Serotonin-Wiederaufnahmehemmern. Psychopharmakotherapie 7: 2–8
MÜLLER WE, ECKERT A (2000) Psychopharmakotherapie: pharmakologische Grundlagen. In: MÜLLER H J, LAUX G, KAPFHAMMER LI-P (Ilrsg) Psychiatrie und Psychotherapie. Springer, Berlin Heidelberg New York Tokio, S 497–542
NELSON DR, PALMER KJ, JOHNSON AM (1990) Effect of prolonged 5-hydroxytryptamine uptake inhibition by paroxetine on cortical beta 1 and beta 2-adrenoceptors in rat brain. Life Sci 47: 1683–1691
NEUVONEN PJ, POHJOI.A-SINTONEN S, TACKE UY, VUORI E (1993) Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet 342: 1419
NOVESKE FG, HAHN KR, FLYNN RJ (1989) Possible toxicity of combined fluoxetine and lithium. Am J Psychiatry 146: 1515
OTTON SV, We D, JOFFE RT, CHRUNG SW, SELLERS EM (1993) Inhibition by fluoxetine of cytochrome P-450 IID6 activity. Clin Pharmacol Ther 53: 401–409
OWENS MJ, IENI JR, KNIGHT DL, WINDERS K, NEMEROFF CB (1995) The serotonergic anti-depressant nefazodone inhibits the serotonin transporter: in vivo and ex vivo studies. Life Sci 57: L373–L380
PICK CG, PAUL D, EISON MS, PASTERNAK GW (1992) Potentiation of opioid analgesia by the antidepressant nefazodone. Eur J Pharmacol 211: 375–381
PRESKORN SH (1996) Clinical pharmacology of selective serotonin reuptake inhibitors. Professional Communications, Caddo, OK, USA
PULLAR IA, CARNEY SL, COLVIN EM, LUCAITES VL, NELSON DL, WEDLEY S (2000) LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine (2A) receptor antagonist: a comparison with the antidepressant nefazodone. Eur J Pharmacol 407: 39–46
RAPEPORT WG, WILLIAMS SA, WARHEAD DC, DEW-LAND PM, TANNER T, WESNES K (1996) Absence of sertraline-mediated effect on the pharmacokinetics and pharmacodynamies of carbamazepine. J Clin Psychiatry 57 [Suppl 1]: 20–23
REDROBE JP, BOURIN M (1998) Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test. Psychopharmacology (Berl) 138: 198–206
RIEDEL M, MULLER N, ¨ªMULLER WE, MÜLLER H-J (2000) Nefazodon, ein dual-serotonerges Antidepressivum. Psychopharmakotherapie 7: 117–124
SANCHEZ C, HYTTEL J (1999) Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 19: 467–489
SANCHEZ C, MEIER E (1997) Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Psycho-pharmacology (Berl) 129: 197–205
SANCHEZ C, TOI-rRUP B (2000) The S-enantiomer of citalopram (Lu 26–054) is a highly selective and potent serotonin reuptake inhibitor. Annual Meeting, Society of Biological Psychiatry (SOBP), Chicago, USA, May 26–054,2000 (Abstract)
ScoTT JA, CREWS FT (1986) Down-regulation of serotonin2, but not of beta-adrenergic receptors during chronic treatment with amitriptyline is independent of stimulation of serotonin2 and beta-adrenergic receptors. Neuropharmacology 25: 1301–1306
SMITlI DL, WENEGRAT BG (2000) A case report of serotonin syndrome associated with combined nefazodone and fluoxetine. J Clin Psychiatry 61: 146
TAYLOR DP, CARIER RB, EISON AS, MULLINS UL, SMITH HL, TORRENTE JR, WRIGHT RN, YOCCA FD (1995) Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry 56 [Suppl 61: 3–11
VON MOLTKE LL, GREENBLATT DJ, GRANDA BW,GRASSI JM, SCI WIDER J, HARMATZ JS, SHARER RI (1999) Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450–3A4 inhibitory actions. Psychopharmacology (Berl) 145: 450–3
WONG DT, REID LR (1986) Suppression of food-intake in meal-fed and 2-desoxyglucose-treated rats by enantiomers of fluoxetine and other inhibitors of monoamine uptake. Fed Proc 45: 609–614
Unerwünschte Wirkungen,Kontraindikationen,Überdosierung, Intoxikation
AGUGI.IA E, CASACCHIA M, CASSANO GB et al. (1993) Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol 8: 197–202
AHLFORS UG, ELOVAARA S, HARMA P et al. (1988) Clinical multi-centre study of citalopram corn-pared double-blindly with mianserin in depressed patients in Finland. Nord Psykiatr Tidsskr 42: 201–210
AHRENS B (1997) Suizidalität. Psychopharmakotherapie 4 [Suppl 51: 28–29
ALTAMURA A, PERCUDANI M, GUERCETTI G, INVERNIzzI G (1989) Efficacy and tolerability of fluoxetine in the elderly: a double-blind study versus amitriptyline. Int Clin Psychopharmacol 4 lSuppl 11: 103–106
AMERICAN PSYCHIATRIC ASSOCIATION (1987) Diag-nostic and statistical manual of mental disorders, 3rd edn, revised. American Psychiatric Association, Washington DC
AMIN MM, ANANTH JV, COLEMAN BS, DARCOURT G, FARKAS T, GOLDSTEIN B, LAPIERRE YD, PAYKEL E, WAKELIN JS (1984) Fluvoxamine: antidepres-sant effects confirmed in a placebo-controlled international study. Clin Neuropharmacol 7:580–581
AMORE M, MAGNANI K, CERISOLI M et al. (1999) Panic disorder. A long-term treatment study: fluoxetine vs imipramine. Hum Psychopharmacol 14: 429–434
AMORE M, MAGNANI K, CERISOLI M (1999h) Short-term and long-term evaluation of selective serotonin reuptake inhibitors in the treatment of panic disorder: fluoxetine vs citalopram. Hum Psychopharmacol 14: 435–440
AMSTERDAM JD, FAWCETT J, QUITKIN FM, REIMHERR FW, ROSENBAUM JF, MICHESLON D, HORNIGROHAN M, BEASLEY CM (1997) Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am J Psychiatry 154: 963–969
ANDERSON I, TOMENSON BM (1994) The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. Psychopharmacology 8: 238–249
ANDERSON IM, TOMENSON BM (1995) Treatment dis-continuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 310: 1433–1438
ANDERSEN G, VESTERGAARD K, RIIS JO (1993) Citalo-pram for post-stroke pathological crying (see comments). Lancet 342: 837–839
ANSARI A (2000) The efficacy of newer antidepressants in the treatment of chronic pain: a review of current literature. Haw Res Psychiatry 7: 257–277
ANSSEAU M, DARIMONT P, LECOQ A, DENAYER A, EVRARD JL, KREMER P, DEVOITILLE JM, DIERICK-M, MERTENS C, MesoTTEN F et al. (1994) Controlled comparison of nefazodone and amitriptyline in major depressive inpatients. Psychopharmacology (Berl) 115: 254–260
ANSSEAU M, GABRIELS A, LOYENS J et al. (1994) Controlled comparison of paroxetine and fluvoxamine in major depression. Hum Psychopharmacol 9: 329–336
ANTON SF, ROBINSON DS, ROBERTS DL, KENSLER TT, ENGLISH PA, ARCHIBALD DG (1994) Long-term treatment of depression with nefazodone. Psychopharmacol Bull 30: 165–169
ARANDA-MICHELJ, KOEHLER A, BEJARANO PA,POULOS JE,LUXON BA, KHAN CM, EE LC, BALISTRERI WF, WEBER FL (1999) Nefazodone-induced liver failure: report of three cases. Ann Intern Med 130: 285–288
ARMINEN SL, IKONEN U, PULKKINEN P et al. (1994) A 12-week double-blind multi-centre study of paroxetin and imipramine in hospitalized depressed patients. Acta Psychiatr Scand 89: 382–389
ARMITAGE R, RUSH AJ, TRIVEDI M, CAIN J, ROFFWARG HP (1994) The effects of nefazodone on sleep architecture in depression. Neuropsychopharmacology 10: 123–127
ARMITAGE R, YONKERS K, COLE D, RUSH AJ (1997) A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients. J Clin Psychopharmacol 17: 161–168
BAKKER A, VAN BALKOM AJ, VAN DYCK R (2000) Selec-tive serotonin reuptake inhibitors in the treatment of panic disorder and agoraphobia. Int Clin Psychopharmacol 15 [Suppl 2]: S25—S30
BALANT-GORGIAAE, GEX-FABRYM, GENET C, BALANT LP (1999) Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors. Ther Drug Monit 21: 105–115
BALDWIN DS(1995)Psychotropic drugs and sexual dysfunction. Int Rev Psychiatry 7: 261–273
BALDWIN DS, HAWLEY CJ, ABED RT, MARAGAKIS BP, Cox J, BUCKINGHAM SA, POVER GH, ASCHER A (1996) A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. J Clin Psychiatry 57: 46–52
BALDWIN DS, THOMAS SC, BIRIWHISTLE J (1997) Ef-fects of antidepressant drugs on sexual function. Int J Psychiatr Clin Pract 1: 47–58
BANK J (1994) A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache 34: 476–478
BARBEY JT, RoosE SP (1998) SSRI safety in over-dose. J Clin Psychiatry 59 [Suppl] 15: 42–48
BARBIAIYA RH, BRADY ME, SHUKLA UA, GREENE DS (1995a) Steady-state pharmacokinetics of nefazodone in subjects with normal and impaired renal function. Eur J Clin Pharmacol 49: 229–235
BARBHAIYA RH, SHUKLA UA, KROBOTH PD, GREENE DS (1995b) Coadministration of nefazodone and benzodiazepines. II. A pharmacokinetic interaction study with triazolam. J Clin Psychopharmacol 15: 320–326
BARBHAIYA RH, SHUKLA UA, NATARAJAN CS, BEHR DA, GREENE DS, SAINATI SM (1995c) Single-and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosis. Clin Pharmacol Ther 58: 390–398
BARBHAIYA RH, SHUKLA UA, GREENE DS (1995d) Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment. Eur J Clin Pharmacol 49: 221–228
BARBHAIYA RH,BUCH AB,GREENE DS (1996a) A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses.J Clin Psychopharmacol 16: 19–25
BARBHAIYA RH, SHUKLA HA, GREENE DS, BREUL HP,MIDHA KK (1996b) Investigation of pharmacokinetic and pharmacodynamie interactions after coadministration of nefazodone and haloperidol. J Clin Psychopharmacol 16: 26–34
BARRELET L, BIAJEV B, BOLZANI L, DE SAUSSURE CH, KASAS A, VAN H, GACHOUD JP (1991) Etude multicentrique comparant l’efficacit¨¦ et la tol¨¦rance du moclob¨¦mide et de la fluvoxamine chez des patients hospitalis¨¦s et ambulatoires presentant un ¨¦pisode d¨¦pressif majeur. Schweiz Rundschau Med (Praxis) 80: 524–528
BEASLEY C, HOLMAN SL, PorvIN JH (1993) Fluoxetine compared with imipramine in the treatment of inpatient depression. Ann Clin Psychiatry 5: 199–208
BEASLEY CM et al, (1992) Fluoxetine: activating and sedating effects at multiple doses. J Clin Psychopharmacol 12: 328–333
BEASLEY CM JR, NILSSON ME, KOKE SC, GONZALES JS (2000) Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20mg/day dose. J Clin Psychiatry 61: 722–728
BECH P (2001) The significance of delusions in depressive disorders. Curr Opin Psychiatry 14: 47–49
BENAZZI F (1998) SSRI discontinuation syndrome related to fluvoxamine. J Psychiat Neurosci 23: 94
BENNIE E, MULLIN JM, MARTINDALE JJ (1995) A dou-ble-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry 56: 229–237
BERMAN RM, DARNELL AM, MILLER HL, ANAND A, CHARNEY DS (1997) Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 154: 37–43
BERSANI G, RAPISARDA V, CIANI N et al. (1994) A double-blind comparative study of sertraline and amitriptyline in outpatients with major depressive episodes. Hum Psychopharmacol 9: 63–68
BIGNAMINI A, RAPISARDA V (1992) A double-blind multicentre study of paroxetine and amitriptyline in depressed outpatients. Int Clin Psychopharmacol 6 [Suppl 41: 37–41
BISSERBE JC,BOYER P,SOUETRE E et al.(1996)A 6-month sertraline fluoxetine comparative study in depressed outpatients:outcome and costs.20th Congress of the International College of Neuropsychopharmacology, June 23–27, Melbourne
BLACK D, WESNER R, BWERS W, GABEL J (1993) A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 50: 44–50
BOUCHARD JM, DELAUNAY J, DELISLE JP et al. (1987) Citalopram versus maprotiline: a controlled, clinical multicentre trial in depressed patients. Acta Psychiatr Scand 76: 583–592
BOUGEROL T, UCHIDA C, GACHOUD JP, KÖHLER M, MIKKELSEN H (1992) Efficacy and tolerability of moclobemide compared with fluvoxamine in depressive disorder (DSM III). A French/Swiss double-blind trial. Psychopharmacology 106: 5102–5108
BOUGEROL T, Scorro JC, PATIO FM et al. (1997) Citalopram and fluoxetine in major depression: comparison of two clinical trials in a psychiatrist setting and in general practice. Clin Drug Invest 14: 77–89
BOUWER C, STEIN DJ (1998) Use of the selective serotonin re-uptake inhibitor citalopram in the treatment of generalized social phobia. J Affect Disord 49: 79–82
BRION F, BRION N, DURIGON M (1996) Fatal over-dose with citalopram? [letter]. Lancet 348: 1380
BROWN MC, NIMMERRICHTER AA, GUEST JF (1999) Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in austria. Eur Psychiatry 14: 230–244
BRUNELLO N, BURROWS G, JÖNNSSON B et al. (1995) Critical issues in the treatment of affective disorders. Depression 3: 187–198
BUCHBERGER R, WAGNER W (2002) Fluvoxamine: safety profile confirmed in extensive post-marketing surveillance. Pharmacopsychiatry 35: 101–108
BURKE WJ, GERGEL I, BOSE A (2002) Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 63: 331–336
BURRAI C, BOCCHETTA A, DEL ZOMPO M (1991) Mania and fluvoxamine. Am J Psychiatry 148: 1263–1264
CANTRELL R, GILLESPIE W, ALTSHULER L (1999) Fluox-etine and sertraline dosages in major depression. Depress Anxiety 9: 78–82
CARPENTER LL, MCDOUGLE CJ, EPPERSON CN, PRICE LH (1996) A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder. Drug Saf 15: 116–134
CHOUINARD G, SAXENA B, BELANGER MC, RAVINDRAN A et al. (1999) A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder. J Affect Disord 54: 39–48
CHRISTIANSEN PE, BEHNKE K, BLACK CH et al. (1996) Paroxetine and amitriptyline in the treatment of depression in general practice. Acta Psychiatr Scand 93: 158–63
CLAGHORN JL, FEIGHNER JP (1993) A double-blind comparison of paroxetine with imipramine in the long-term treatment of depression. J Clin Psychopharmacol 13 [Suppl 21: 23–27
COFFEY DJ, JENKYN LR, RICHTER EM (1994) A double-blind comparison of sertraline and nortriptyline in the treatment of depressed geriatric outpatients. Vllth European College of Neuropsychopharmacology, Jerusalem, Israel, October 16–21, 1994
COHN JB, WILCOX C (1985) A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. J Clin Psychiatry 46: 26–31
COHN CK,SHRIVASTAVA R,MENDELS J et al(1990)Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry 51 [Suppl 12B]: 28–33
COHN CK, ROBINSON DS, ROBERTS DL, SCHWIDERSKI UF., O’BRIEN K, LENI JR (1996a) Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression. J Clin Psychiatry 57: 15–18
COHN CK, ROBINSON DS, ROBERTS DL, SCHWIDERSKI UE, O’BRIEN K, IENI JR (1996b) Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression. J Clin Psychiatry 57: 15–18
COLEMAN BS, BLOCK BA (1982) Fluvoxamine male-ate, a serotonergic antidepressant: a comparison with chlorimipramine. Prog Neuropsychopharmacol Biol Psychiatry 6: 475–478
COUPLAND N, WILSON S, Nun. D (1997) Antidepressant drugs and the cardiovascular system: a comparison of tricyclics and selective serotonin re-uptake inhibitors and their relevance for the treatment of psychiatric patients with cardiovascular problems. J Psychopharmacol 11: 83–92
DANISH UNIVERSITY ANTIDEPRESSANT GROUP (1986)Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology 90:131–138
DASGUPTA K (1990) Additional cases of suicidal ideation associated with fluoxetine [letter]. Am J Psychiatry 147: 1570
DAVIDSON JR (1997) Biological therapies for post-traumatic stress disorder: an overview. J Clin Psychiatry 58: 29–32
DAVIDSON JR (2000) Pharmacotherapy of post-traumatic stress disorder: treatment options, long-term follow-up, and predictors of outcome. J Clin Psychiatry 61: 52–56 discussion 57–59
DAVIDSON J, ROTHBAUM B, VAN DER KOLK B et al. (2001) Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry 58: 485–492
DAVIS R, WHITTINGTON R, BRYSON HM (1997) Ne-fazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs 53: 608–636
DEJONGHE F, SWINKELS J, TUYNMAN-QUA H (1991) Randomized double-blind study of fluvoxamine and maprotiline in treatment of depression. Pharmacopsychiatry 24: 21–27
DEJONGHE F, RAVELLI DP, TUYNMAN-QUA H (1991) A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major depression. Pharmacopsychiatry 24: 62–67
DEMARTINIS NA, SCHWEIZER E, RICKELS K(1996) An open-label trial of nefazodone in high comor-bidity panic disorder. J Clin Psychiatry 57: 245–248
DEMLUNG J, EBERT D (1993) Nicht-trizyklische Antidepressiva-Klinik-SSRI. In: RIEDERER P, LAUX G, POLDINGER W (Hrsg) Neuro-Psychopharmaka, Bd 3. Antidepressiva und Phasenprophylaktika. Springer, Wien New York, S 127–251
DEN BOER J, WESTENBERG HGM (1988) Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 3: 59–74
DEVANE CL (1999) Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell Mol Neurobiol 19: 443–466
DEWAN MJ, ANAND VS (1999) Evaluating the tolerability of the newer antidepressants. J Nerv Ment Dis 187: 96–101
DE WILDE J, MERTENS C, OVERO KF et al. (1985) Citalopram versus mianserin. A controlled, double-blind trial in depressed patients. Acta Psychiatr Scand 72: 89–96
DE WILDE J, SPIERS R, MERTENS C et al. (1993a) Adouble-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 87: 141–145
DE WILDE J, SPIERS R, MERTENS C et al. (1993b) A double-blind comparative multicentre study comparing paroxetine with fluoxetine in depressed patients. Hosp Formul 28: 36–40
DIERICK M, RAVIZZA L, REALINI R, MARTIN A (1996) A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry 20: 57–71
DITTMANN RW, LINDEN M, OSTERHEIDER M, SCHAAF B, OHNMACHT U, WEBER HJ (1997) Antidepressant drug use: differences between psychiatrists and general practitioners. Results from a drug utilization observation study with fluoxetine. Pharmacopsychiatry 30: 28–34
DITTMANN RW, CZEKALLA J, HUNDEMER HP, LINDEN M (2000) Efficacy and safety findings from naturalistic fluoxetine drug treatment in adolescent and young adult patients. J Child Adolesc Psychopharmacol 10: 91–102
DOCKENS RC, RAPOPORT D, ROBERTS D, GREENE DS, BARBHAIYA RH (1995) Lack of an effect of nefazodone on the pharmacokinetics and pharmacodynamics of theophylline during concurrent administration in patients with chronic obstructive pulmonary disease. Br J Clin Pharmacol 40: 598–601
DOCKENS RC, GREENE DS, BARBHAIYA RH (1996a) Assessment of pharmacokinetic and pharma-codynamic drug interactions between nefazodone and digoxin in healthy male volunteers. J Clin Pharmacol 36: 160–167
DOCKENS RC, GREENE DS, BARBHAIYA RH (1996b) The lack effect of food on the bioavailability of nefazodone tablets. Biopharm Drug Dispos 17: 135–143
DOOGAN DP, LANGDON CJ (1994) A double-blind, placebo-controlled comparison of sertraline and dothiepin in the treatment of major depression in general practice. Int Clin Psychopharmacol 9: 95–100
DUARTE A, MIKKELSEN H, DELINI-STULA A (1996) Moclobemide versus fluoxetine for double depression: a randomized double-blind study. J Psychiatr Res 30: 453–458
DUNNER DL (1998) Treatment dysthymic disorder. Depress Anxiety 8: 54–58
EBERT D, ALBERT R, MAY A, MERZ A, MURATA H, STOSIEK I, ZAHNER B (1997) The serotonin syndrome and psychosis-like side-effects of fluvoxamine clinical use - an estimation of incidence. Eur Neuropsychopharmacol 7: 71–74
EDWARDS JG (1997) Prevention of relapse and recurrence of depression: newer versus older antidepressants. Adv Psychiatr Treat 3: 52–57
EDWARDS JG, ANDERSON I (1999) Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 57: 507–533
EDWARDS JG, GOLDIE A, PAPAYANNI-PAPASTHATIS S (1989) The effect of paroxetine on the electrocardiogram. Psychopharmacology 97: 96–98
EDWARDS J, INMAN WHW, WILTON LW, PEARCE GL (1994) Prescription-event monitoring of 10 401 patients treated with fluvoxamine. Br J Psychiatry 164: 387–395
EDWARDS RA, NEWBURN G (1994) Sertraline vs CIO-mipramine in major depression: a single blind trial. 29th Congress of the Royal Australian and New Zealand College of Psychiatrists, Tasmania, May 15–19, 1994
EINARSON TR, ARIKIAN SR, CASCIANO J, DOYLE JJ (1999) Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clin Ther 21: 296–308
EKSEI.IUS L, VON KNORRING L, EBERHARD G (1997) A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice. Int Clin Psychopharinacol 12: 323–331
EMSLIE GJ, RUSH AJ, WEINBERG WA, KOWATCH RA, CARMODYT, MAYES TL (1998) Fluoxetine in child and dolescent depression: acute and maintenance treatment. Depress Anxiety 7: 32–39
FABRE LF, SCHARF MB, ITIL TM (1991) Comparative efficacy and safety of nortriptyline and fluoxetine in the treatment of major depression: a clinical study. J Clin Psychiatry 52: 62–67
FABRE LF, ABUZZAHAB FS, AMIN M et al. (1995) Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry 38: 592–602
FAWCETT J, MARCUS RN, ANTON SF, O’BRIEN K,SCHWI-DERSKI U (1995) Response of anxiety and agitation symptoms during nefazodone treatment of major depression. J Clin Psychiatry 56: 37–42
FEIGER A, KIEV A, SIIRIVASTAVA RK, WISSELINK PG, WILCOX CS (1996) Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 57: 53–62
FEIGHNER J, COHN JB (1985) Double-blind comparative trials of fluoxetine and doxepine in geriatric patients with major depressive disorder. J Clin Psychiatry 46: 20–25
FEIGHNER JP, OVER K (1999) Multicenter, placebo-controlled, fixed dose study of citalopram in moderate to severe depression. J Clin Psychiatry 60: 824–830
FEIGHNER JP, BOYER WF, MEREDITH CH, HENTDRICK-SON GG (1989) A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression. Int Clin Psychopharmacol 4: 239–244
FEIGHNER JP, PAMBAKIAN R, FOWLER RC, BOYER WE, D’AMtco MF (1989) A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression. Psychopharmacol Bull 25: 219–221
FEIGHNER JP, COHN JB, FABRE JR LF et al. (1993) A study comparing paroxetine, placebo and imipramine in depressed patients. J Affect Disord 28: 71–79
FEIGHNER JP, BENNE TT ME, ROBERTS DL et al. (1996) A double-blind trial of nefazodone versus placebo in depressed inpatients [abstract no: NR370]. 149th Meeting of the American Psychiatric Association, New York, p 168
FERGUSON JM (2001) The (effects of antidepressants on sexual functioning in depressed patients: a review. J Clin Psychiatry 62: 22–34
FERSLEW KE, HAGARDORN AN, HARLAN GC, MCCOR-MICK WF (1998) A fatal drug interaction between clozapine and fluoxetine. J Forensic Sci 43: 1082–1085
FICHTER M, LEIBL K, KRÜBER R, RIEF W (1991) Fluox-etine versus placebo: a double-blind study with bulimic inpatients undergoing intensive psychotherapy. Pharmacopsychiatry 24: 1–7
FINDLING RL, REED MD, BLUMER JL (1999) Pharmacological treatment of depression in children and adolescents. Paediatr Drugs 1: 161–182
FLICKER C, TANGHoJ P, TSAY JY (1998) Meta-analysis of placebo-controlled trials of citalopram in the treatment of depression. American Psychiatric Association Meeting, Toronto, Ontario, Canada FONTAINE R (1991) The efficacy and safety of sertraline versus imipramine in outpatients with major depression: a six month, double-blind, parallel multicenter study. IVth European College of Neuropsychopharmacology, Monte Carlo, Monaco, October 6–9, 1991
FONTAINE R, ONTIVEROS A, ELIE R, KENSLER TT, ROBERTS DL, KAPLITA S, EcKER JA, FALUDI G (1994) A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry 55: 234–241
FRANCHINI L, ROSSINI D, BONGIORNO F, SPAGNOLO C, SMERALDI E, ZANARDI R (2000) Will a second prophylactic treatment with a higher dosage of the same antidepressant either prevent or delay new depressive episodes? Psychiatry Res 96: 81–85
FREY R, SCHREINZER D, STIMPFL T, VYCUDILIK W, BERZLANOVICH A, KASPER S (2000) Suicide by antidepressant intoxication at autopsy in Vienna between 1991–1997: the favourable consequences of the increasing use of SSRIs. Eur Neuropsychopharmacol 10: 1991–1997
GAGIANO CA (1993) A double blind comparison of paroxetine and fluoxetine in patients with major depression. Br J Clin Res 4: 145–152
GILLIN JC, RAPAPORT M, ERMAN MK, WINOKUR A, AL-BATA BJ (1997) A comparison of nefazodone and fluoxetine on mood and on objecitve, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial. J Clin Psychiatry 58: 185–192
GINESTET D (1989) Fluoxetine in endogenous depression and melancholia versus clomipramine. Int J Psychopharmacol 4 [Suppl 1]: 37–40
GLASSMAN AH (1997) Citalopram toxicity [letter]. Lancet 350: 818
GLEITER C, VoLZ HP, MOLLER HJ (1999) SerotoninWiederaufnahmehemmer. Wissenschaftliche Verlagsgesellschaft, Stuttgart
GOLDSTEIN DJ, CORBIN LA, SUNDELL KL (1997) Ef-fects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 89: 713–718
GOODMAN W, PRICE L, DELGADO P et al. (1990) Specificity of serotonin reuptake inhibitors in the treatment of obsessive-complusive dis-orders: comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 47: 577–585
GOODMAN WK, WARD H, KABLINGER A, MURPHY T (1997) Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions. J Clin Psychiatry 58: 32–49
GRAM L (1994) Fluoxetine. NEJM 331: 1354–1361
GRASSI B, GAMBINI O, SCARONE S (1995) Notes on the use of fluvoxamine as treatment of depression in HIV-1-infected subjects. Pharmacopsychiatry 28: 93–94
GRAVEM A, AMTHOR KF, ASTRUP C et al. (1987) A double-blind comparison of citalopram (Lu 10–171) and amitriptyline in depressed patients. Acta Psychiatr Scand 75: 10–171
GREENE DS, BARBHAIYA RH (1997) Clinical pharmacokinetics of nefazodone. Clin Pharmacokinet 33: 260–275
GREENE DS, SALAZAR DE, DOCKENS RC, KROBOTH P, BARBHAIYA RH (1995) Coadministration of nefazodone and benzodiazepines. III. A pharmacokinetic interaction study with alprazolam. J Clin Psychopharmacol 15: 399–408
GREENE DS, SALAZAR DE, DOCKENS RC, KROBOTH P, BARBHAIYA RH (1995) Coadministration of nefazodone and benzodiazepines. IV. A pharmacokinetic interaction study with lorazepam. J Clin Psychopharmacol 15: 409–416
GREIST J,JEFFERSON JW,KOBAK KA et al.(1995) fficacy and tolerability of serotonin transport inhibitors on obsessive-compulsive disorder. Arch Gen Psychiatry 52: 53–60
GROUP FBNS(1992)Fluoxetine in the treatment of bulimia nervosa. Arch Gen Psychiatry 49:139–147
GUELFI JD,WISEMAN RL (1995) The treatment of dysthymia with sertraline: a double-blind placebo-controlled trial in dysthymic outpatients without major depression. VIIIth European College of Neuropsychopharmacology, Venice, Italy, September 30 — October 4, 1995
GUELFI JD, DREYFUS JF, PICHOT P (1983) A double-blind controlled clinical trial comparing fluvoxamine with imipramine. Br J Clin Pharmacol 15: 411S–417S
HADDAD P, LEJOYEUX M, YOUNG A (1998) Anti-depressant discontinuation reactions. BMJ 316: 1105–1106
HAFFMANS PMJ, TIMMERMAN L, HOOGDUIN CAL et al. (1996) Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. Int Clin Psychopharmacol 11: 157–164
HAMILTON M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56–62
HARRIS B, SZULECKA TK, ANSTEE JA (1991) Fluvox-amine versus amitriptyline in depressed hospital out-patients: a multicentre double-blind comparative trial. Br J Clin Res 2: 89–99
HARTTER S, WETZEL H, IIAMMES E, TORKZADEH M, HIEMKE C (1998) Serum concentrations of fluvoxamine and clinical effects. A prospective open clinical trial. Pharmacopsychiatry 31: 199–200
HEALY D (1994) The fluoxetine and suicide controversy. A review of the evidence. CNS Drugs 1: 223–231
HEILIGENSTEIN J, TOLLEFSON GD, FARIES DE (1993) A double-blind trial of fluoxetine, 20 mg, and placebo in out-patients with DSM-III-R major depression and melancholia. Int Clin Psychopharmacol 8: 247–251
HELLERSTEIN D, YANOWITCH P, ROSENTHAL J et al. (1993) A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia. Am J Psychiatry 150: 1169–1175
HENRY JA (1997) Toxicity of newer versus older antidepressants. Adv Psychiatr Treat 3: 41–45
HENRY JA, ALEXANDER CA, SENER EK (1995) Relative mortality from overdose of antidepressants. BMJ 310: 221–224
HILGER E, PRASCHAK-RIEDER N, WILLEIT M, STASTNY, J, KONSTANTINIDIS A, NEUMEISTER A, KASPER S (2002) Die Pharmakotherapie der saisonal abhängigen Depression. Nervenarzt 73: 22–31
HOCHBERG HM, KANTER D, HoUSER VP (1995) Elec-trocardiographic findings during extended clinical trials of fluvoxamine in depression: one years experience. Pharmacopsychiatry 28: 253–256
HOCHSTRASSER B, ISAKSEN PM, KOPONEN H et al. (2001) Prophylactic effect of citalopram in unipolar, recurrent depression: a placebo-controlled study on maintainence therapy. Br J Psychiatry 178: 304–310
HOLLAND JC, ROMANO SJ, HEILIGENSTEIN JH, TEPNER RG, WILSON MG (1998) A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psychooncology 7: 291–300
HOTOPF M, HARDY R, LEWIS G (1997) Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. Br J Psychiatry 170: 120–127
HUMBLE M (2000) Noradrenaline and serotonin reuptake inhibition as clinical principles: a review of antidepressant efficacy. Acta Psychiatr Scand [Supplj 402: 28–36
HURST M, LAMB HM (2000) Fluoxetine. A review of its use in anxiety disorders and mixed anxiety and depression. CNS Drugs 14: 51–80
HYTTEL J, ARNT J, SANCHEZ C (1995) The pharma-cology of citalopram. Rev Contemp Pharmacother 6: 271–85
IsACssoN G, HOLMGREN P, DRUID H, BERGMAN U (1997) The utilization of antidepressants - a key issue in the prevention of suicide: an analysis of 5281 suicides in Sweden during the period 1992–1994. Acta Psychiatr Scand 96: 1992–1994
JENSEN PN, OLESEN OV, BERTELSEN A et al. (1997) Citalopram and desmethylcitalopram concentrations in breast milk and in serum of mother and infant. Ther Drug Monit 19: 236–239
KAPITANY T, SCHINDL M, SCHINDLER SD, HESSELMANN B, FüREDER T, BARNAS C, SIEGHART W, KASPER S (1999) The citalopram challenge test in patients with major depression and in healthy controls. Psychiatry Res 88: 75–88
KARLSSON I, GODDERIS J, AI:GUJSTO DE,MENDONCA LIMA C et al. (2000) A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia. Int J Geriatr Psychiatry 15: 295–305
KASAS A, REYNAERT C, LARUELLE M et al. (1994) A double-blind study of paroxetine and maprotiline in major depression [abstract]. Neuropsychopharmacology 11: 274
KASPER S (1996) Citalopram - Profil eines modernen Antidepressivums. Psychopharmakotherapie 4: 146–151
KASPER S (1997a) Blickpunkt Sertralin. Blaue Reihe. Aesopus-Verlag, Stuttgart KASPER S (1997b) Long-term treatment of depression with antidepressants. Evidence from clinical trials, prediction and practical guidelines. In: HONIG A, VAN PRAAG HM (eds) Depression, neurobiological, psychopathological and therapeutic advances. Wiley, Chichester, pp 499–518
KASPER S (1998) Angsterkrankungen: Diagnostik und Pharmakotherapie. MMV Medizin Verlag, München KASPER S, KASPER A (1994) Langzeitbehandlung affektiver Störungen. Nervenarzt 65: 577–589
KASPER S, HEIDEN A (1995) Do SSRIs differ in their antidepressant efficacy? Hum Psychopharmacol 10: 163–171
KASPER S, MOLLER HJ (1995) Antidepressive Psychopharmakotherapie. Selektive SerotoninWiederaufnahmehemmer (SSRI) als neues Wirkprinzip. Dtsch Ärzteblatt 92: A-428–434
KASPER S, SCHATZBERG A (2000) Future directions in antidepressants and mood stabilizing agents. In: BUCKLEY P, WADDINGTON J (eds) Schizophrenia and mood disorders. The new drug therapies in clinical practice. Butterworth & Heinemann, Oxford Auckland Boston Johannisburg Melbourne New Delhi, pp 212–219
KASPER S, FUGER J, MÖLLER HJ (1992) Comparative efficacy of antidepressants. Drugs 43 [Suppl 21: 11–23
KASPER S, LEPINE JP, MENDLEWICZ J, MONTGOMERY SA, RUSH AJ (1994/1995) Efficacy, safety and indications for tricyclic and newer antidepressants. Depression 2: 127–137
KASPER S, MOLLER HJ, MONTGOMERY SA, ZONDAG E (1995) Antidepressant efficacy in relation to item analysis and severity of depression: a placebo-controlled trial of fluvoxamine versus imipramine. Int Clin Psychopharmacol 9 1Suppl 41: 3–12
KASPER S, MÖLLER HJ, MÜLLER-SPANN F (1997) De-pression. Diagnose und Pharmakotherapie. Thieme, Stuttgart
KASPER S, FREY R, SCHREINZER D (2001) Safety and tolerability of old and new antidepressants. In: DEN BOER JA, WESTENBERG H (eds) Focus on psychiatry. Antidepressants: selectivity or multiplicity? Benecke, Amsterdam, pp 157–169
KASPER S, LOFT H, SMITZ JR (2002) Escitalopram is efficacious and well tolerated for the treatment of social anxiety disorder. 2nd Annual Meeting, Scandinavian College of Neuropsychopharmacology (SCNP), Juan les Pins, France, April 10–12, 2002 (Abstract)
KAYA N, HERKEN H, RASKIN R, TELCIOGLU M, CILLI AS (1998) Citalopram versus venlafaxin in the treatment of major depression. Eur Neuropsychopharmacol 8 [Suppl 1]: 28
KELLER MB (2000) Citalopram therapy for depression: a review of 10 years of European experience and data from U.S. clinical trials. J Clin Psychiatry 61: 896–908
KELLER MB, Kocsis JH, THASE ME, GELENBERG AJ, RUSH AJ, KORAN L, SCHATZBERG A, RUSSELL J, HIRSCHFELD R, KLEIN D, MCCULLOUGH JP, FAWCETT JA, KORNSTEIN S, LAVANGE L, HARRISON W (1998) Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. JAMA 280: 1665–1672
KIEv A, FEIGER A (1997) A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. J Clin Psychiatry 58: 146–152
KLYSNER R, PLEDRUB E, HANSEN HL et al. (2000) The effectiveness of citalopram in the prevention of depression recurrence in elderly patients. Annual Meeting of the American Psychiatric Association, Chicago, USA
Kocsis JH (1995) Acute and long term pharmacotherapeutic strategies in pure dysthymia: efficacy of sertraline and imipramine. VIIth European College of Neuropsychopharmacology, Jerusalem Israel, October 16–21, 1995
KORAN LM, CAIN JW, DOMINGUEZ RA, RUSH AJ, THIEMANN S (1996) Are fluoxetine plasma lev-els related to outcome in obsessive-lev-els disorder? Am J Psychiatry 153: 1450–1454
KYLE CJ, PETERSEN HE, OVERØ KF (1998) Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice. Depress Anxiety 8: 147–153
LANE R, BALDWIN D, PRESKORN S (1995) The SSRIs: advantages, disadvantages and differences. J Psychopharmacol 9 [Suppl 1]: 163–178
LEINONEN E, SKARSTEIN J, BEHNKE K et al. (1999) Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Int Clin Psychopharmacol 14: 329–337
LENZINGER E, DIAMANT K, VYTISKA-BINSTORFER E, KASPER S (1997) Prämenstruelle dysphorische Störung (PMDS). Nervenarzt 68: 708–718
LEPINE JP, GOGER J, BLASHKO C, PROBST C, MOLES MF, KOSOLOWSKI J, SCHARFE IIER B, LANE RM (2000) A double-blind study of the efficacy and safety of sertraline and clomipramine in outpatients with severe major depression. Int Clin Psychopharmacol 15: 263–271
LEPOLA UM, WADE AG, LEINONEN EV et al. (1998) A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry 59: 528–534
LINDEN M (1997) Die Behandlung geriatrischer and gerontopsychiatrischer Patienten mit Fluoxetin. Psychopharmakotherapie 4 [Suppl 51: 43–47
LINNOILA M, STAPLETON JM, GEORGE DT, LANE E, ECKARDT MJ (1993) Effects of fluvoxamine, alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in healthy volunteers. J Clin Psychopharmacol 13: 175–180
LONDBORG P, HEGEL M, GOLDSTEIN S et al. (2001) Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open-label continuation treatment. J Clin Psychiatry 62: 325–331
LOPEZ-IBOR J, SAIZ J, CoTrRAOx J et al. (1996a) Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder. Eur Neuropsychopharmacol 6: 111–118
LOPEZ-IBOR J, GuELFI JD, PLETAN Y, TouRNOUx A, Nos. JF (1996b) Milnacipran and selecitve serotonin reuptake inhibitors in major depres-sion. Int Clin Psychopharmacol 11 [Suppl 41: 41–46
LU ML, LANE HY, CHEN KP, JANN MVP, Su MH, CHANG WI-I (2000) Fluxoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatry 61: 594–599
LYDIARD RB, STAHL SM, HERTZMAN M, HARRISON WM (1997) A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression. J Clin Psychiatry 58: 484–491
MACKAY FR, DUNN NR, MARTIN RM, PEARCE GL, FREEMANTLE SN, MANN RD (1999) Newer antidepressants: a comparison of tolerability in general practice. Br J Gen Pract 49: 892–896
MANN JJ, KAPUR S (1991) The emergence of suicidal ideation and behavior during antidepressant pharmacotherapy. Arch Gen Psychiatry 48: 1027–1032
MANNA V, BOLINO F, DI Cicco L (1994) Chronic tension-type headache, mood depression and serotonin: therapeutic effects of fluvoxamine and mianserine. Headache 34: 44–49
MARKOWITZ JS, DEVANE CL, LISTON HL et al. (2000) An assessment of selective serotonin re-uptake inhibitor discontinuation symptoms with citalopram. Int Clin Psychopharmacol 15: 329–333
MARTIN A, TEBBS VM, ASHFORD JJ (1987) Affective disorders in general practice. Treatment of 6000 patients with fluvoxamine. Pharmatherapeutica 5: 40–49
MASAND P, GUPTA S, DEWAN M (1991) Suicidal ide-ation relating to fluoxetine treatment (letter]. N Engl J Med 324:420
MASSANA J (1998) Rehoxetine versus fluoxetine: an overview of efficacy and tolerability. J Clin Psychiatry 59: 8–10
MCGRATH PJ, STEWART JW, PETKOVA E, QUITKIN FM, AMSTERDAM JD, FAW CETr J, REIMI IERR FW, ROSEN- BAUM JF, BEASLEY CM JR (2000) Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression. 1 Clin Psychiatry 61: 519–524
MENDELS J, REIMHERR F, MARCUS RN, ROBERTS DL et al. (1995) A double-blind, placebo-controlled trial of two close ranges of nefazodone in the treatment of depressed out patients. J Clin Psychiatry 56 [Suppl 61: 30–36
MENDELS J, KIEV A, FABRE LF (1999) Double-blind comparison of citalopram and placebo in depressed out-patients with melancholia. Depress Anxiety 9: 54–60
MENDLEWICZ J (1992) Efficacy of fluvoxamine in severe depression. Drugs 43 [Suppl 21: 32–39
MICHELSON D, LYDIARD RB, POLLACK MH, TAMURA RN, HooG SL, TEPNER R, DEMITRACK MA, TOLLEFSON GD (1998) Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry 155: 1570–1577
MOLLER H (1992) Antidepressants - do they decrease or increase suicidality? Pharmacopsychiatry 25: 249–253
MOLLER H, STEINMEYER EM (1994) Are serotonergic reuptake inhibitors more potent in reducing suicidality? An empirical study on paroxetine. Eur Neuropsychopharmacol 4: 55–59
MOLLER H, You HP (1996) Drug treatment of depression in the 1990s - an overview of achievements and future possibilities. CNS Drugs 52: 625–638
MOLLER HJ, BERZEWSKI H, ECKMANN F et al. (1993) Double-blind multicentre study of paroxetine and amitriptyline in depressed inpatients. Pharmacopsychiatry 26: 75–78
MOLLER HJ, GALLINAT J, HEGERL J, ARATÓ M, JANK Z, PFLUG B, BAUER H (1998) Double-blind, multicenter comparative study of sertraline and amitriptyline in hospitalized patients with major depression. Pharmacopsychiatry 31: 170–177
MOLLER HJ, GLASER K, LEVERKIJS F, GOEBEL C (2000) Double-blind, multicenter comparative study of sertraline versus amitriptyline in outpatients with major depression. Pharmacopsychiatry 33: 206–212
MONTEJO-GONZALEZ AL, LLORCA G, IZQUIERDO JA et al. (1997) SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 23: 176–194
MONTGOMERY SA, ASBERG M (1979) A new depres-sion scale designed to be sensitive to change. Br J Psychiatry 134: 382–389
MONTGOMERY SA, DUNBAR G (1993) Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 8: 189–195
MONTGOMERY S, DUFOUR H, BRION S et al. (1988) The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry 153 [Suppl 3]: 69–76
MONTGOMERY SA, RASMUSSEN JG, LYBY K et al. (1992) Dose response relationship of citalo-pram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression. Int Clin Psychopharmacol 6: 65–70
MONTGOMERY SA, RASMUSSEN JG, TANGHOJ P (1993) A 24-week study of 20 mg citalopram, 40 mg citalopram and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 8: 181–188
MONTGOMERY SA, HENRY J, MACDONALD G et al. (1994a) Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 9: 47–53
MONTGOMERY SA, PEDERSEN V, TANGHOJ P et al. (1994b) The optimal dosing regimen for citalopram - a-meta-analysis of nine placebo-controlled studies. Int Clin Psychopharmacol 9 [Suppl1]: 35–40
MONTGOMERY SA, KASPER S, STEIN D, HEDEGAARD KB, LEMMING OM (2001) Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive compulsive disorder. Int Clin Psychopharmacol 16: 75–86
MONTGOMERY SA, LOFT H, SANCHEZ C et al. (2001) Escitalopram (5-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Pharmacol Toxicol 88: 282–286
MOON CAL, JESINGER DK (1991) The effects of psychomotor performance of fluvoxamine versus mianserin in depressed patients in general practice. Br J Clin Pract 45: 259–262
MooN C, VINCE M (1996) Treatment of major de-pression in general practice: a double-blind comparison of paroxetine and lofepramine. Br J Clin Pract 50: 240–244
MOON CAL, JAGO W, WOOD K et al. (1994) A double-blind comparison of sertraline and clomipramine in the treatment of major depressive disorders and associated anxiety in general practice. J Psychopharmacol 8: 171–176
MOSCOVITCH A, BLASHKO C, WISEMAN R et al. (1995) A double-blind, placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder. 148th American Psychiatric Association, Miami, USA, May 2025, 1995
MOURILHE P, STOKES PE (1998) Risks and benefits of selective serotonin reuptake inhibitors in the treatment of depression. Drug Saf 18: 57–82
MUIJEN M, ROY D, SILVERSTONE T, MEHMET A, CHRIS-TIE M (1988) A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients. Acta Psychiatr Scand 78: 384–390
MULDOON C (1996) The safety and tolerability of citalopram. Int Clin Psychopharmacol 11: 35–40
NELSON EC (1994) An open-label study of nefazodone in the treatment of depression with and without comorbid obsessive compulsive disorder. Ann Clin Psychiatry 6: 249–253
NELSON JC (1998) Augmentation strategies with serotonergic-noradrenergic combinations. J Clin Psychiatry 59: 65–68; discussion 69
NEMEROPE C, NINAN PT, BALLENGER J et al. (1995) Double-blind multicenter comparison of flu-voxamine versus sertraline in the treatment of depressed outpatients. Depression 3: 163–169
NEUMEISTER A,PRASCHAK-RIEDER N, HESSELMANN B, TAUSCHER J, KASPER S (1997) Der Tryptophandepletionstest - Grundlagen and klinische Relevanz. Nervenarzt 68: 556–562
NEUMEISTER A, TURNER EH, MATTHEWS JR, POSTOLACHE TT, BARNETT RL, RAUH MM, VETTICAD RG, KASPER S, ROSENTHAL NE (1998) Effects of tryptophan depletion vs catecholamine depletion in patients with seasonal affective disorder in remission with light therapy. Arch Gen Psychiatry 55: 524–530
NEWHOUSE PA (1996) Use of serotonin selective reuptake inhibitors in geriatric depression. J Clin Psychiatry 57: 12–22
NEWHOUSE PA, RICHTER EM (1994) SSRI in de-pressed elderly: a double-blind comparison of sertraline and fluoxetine in depressed geriatric outpatients. XIXth Collegium Internationale Neuropsychopharmacologicum, Washington DC, USA, June 27 - July 1, 1994
NEWHOUSE PA, KRISHNAN KR, DORAISWAMY PM, RICHTER EM et al. (2000) A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin Psychiatry 61: 559–568
NIELSEN B, BEHNKE K, ARUP P et al. (1993) A com-parison of fluoxetine and imipramine in the treatment of outpatients with major depressive disorder. Acta Psychiatr Scand 87: 269–272
NORTON KRW, SIRELING LI, BHAT AV, RAo B, PAYKEL ES (1984) A double-blind comparison of fluvoxamine, imipramine and placebo in depressed patients. J Affect Disord 7: 297–308
NURNBERG HG, THOMPSON PM, HENSLEY PL (1999) Antidepressant medication change in a clinical treatment setting: a comparison of the effectiveness of selective serotonin reuptake inhibitors. J Clin Psychiatry 60: 574–579
NURNBERG HG, HENSLEY PL, THOMPSON PM, PAINE SS (1999) Modeling the pharmacoeconomic cost of three selective serotonin reuptake inhibitors. Psychiatr Sew 50: 1351–1353
NYTH AL, GOTTERIES CG, LYBY K et al. (1992) A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 86: 138–145
Si/ HRBERG S, CHRISTIANSEN PE, SEVERIN B et al. (1992) Paroxetine and imipramine in the treatment of depressive patients in psychiatric practice. Acta Psychiatr Scand 86: 437–444
OLIE JP, GUNN KP, KATZ E (1994) Sertraline: efficacy and toleration in major depression. XIXth Collegium Internationale Neuropsychopharmacologicum, Washington DC, USA, June 27 - July 1, 1994
ONTIVEROS A, GARCIA-BARRIGA C (1997) A double-blind, comparative study of paroxetine and fluoxetine in out-patients with depression. Br J Clin Res 8: 23–32
OSTERHEIDER M, DITTMANN RW, LINDEN M (1997) Das Nebenwirkungsspektrum von Fluoxetin. Psychopharmakotherapie 4 [Suppl 5]: 39–42
OTTEVANGER E (1991) Fluvoxamine activity profile with special emphasis on the effect on suicidal ideation. Eur J Clin Res 1: 47–54
OTTEVANGER EA (1995) Fluvoxamine and clomipramine in depressed hospitalised patients: results from a randomised, double-blind study. Encephale 21: 317–321
PACHER P, UNGVARI Z, KECSKEMETI V, FURST S (1998) Review of cardiovascular effects of fluoxetine, a selective serotonin reuptake inhibitor, compared to tricyclic antidepressants. Curr Med Chem 5: 381–390
PALMER K, BENFIELD P (1994) Fluvoxamine. An overview of its pharmacological properties and review of its therapeutic potential in non-depressive disorders. CNS Drugs 1: 57–87
PANDE A, SAYLER ME (1993) Severity of depression and response to fluoxetine. Int Clin Psychopharmacol 8: 243–245
PATRIS M, BOUCHARD JM, BOUGEROL T et al. (1996) Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol 22: 129–136
PEARLSTEIN T (2000) Antidepressant treatment of posttraumatic stress disorder. J Clin Psychiatry 61: 40–43
PEREZ A, ASHFORD JJ (1990) A double-blind, randomized comparison of fluvoxamine with mianserin in depressive illness. Curr Med Res Opin 12: 234–241
PERSONNE M, SJOBERG G, PERSSON H (1997) Citalo-pram overdose-review of cases treated in Swedish hospitals (published erratum appears in J Toxicol Clin Toxicol 35: 577). J Toxicol Clin Toxicol 35: 237–240
PERUGI G, GIANNOTII D, DI VAIO S, FRARE F, SAET TONI M, CASSANO GB (1996) Fluvoxamine in the treatment of body dysmorphic disorder (dys-morphophobia). Int Clin Psychopharmacol 11: 247–254
PEZAWAS L, KASPER S (2001) Paroxetine in panic disorder with agoraphobia. Int J Psychiatr Clin Pract 5: 279
PHANJOO A, WONNACOTT S, HODGSON A (1991) Double blind comparative multicenter study of fluvoxamine and mianserin in the treatment of major depressive episodes in elderly people. Acta Psychiatr Scand 83: 476–479
PHILLIPS S, BRENT J, KULIG K, HEILIGENSTEIN J, BIR-KETT M (1997) Fluoxetine versus tricyclic antidepressants: a prospecitve multicenter study of antidepressant drug overdoses. The Antidepressant Study Group. J Emerg Med 15: 439–445
PHILLIPS KA, DWIGHT MM, MCELROY SL (1998) Efficacy and safety of fluvoxamine in body dys-morphic disorder. J Clin Psychiatry 59: 165–171
PICCINELLI M, PINT S, BEI.LANTIIONO C, WILKINSON G (1995) Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br J Psychiatry 166: 424–443
PIGOTT TA, SEAY SM (1999) A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 60: 101–106
PINE D (2001) Fluvoxamine in the treatment of anxiety disorders. A controlled study in children. NEJM 344: 1279–1283
PIRKER W, ASENRAUM S, KASPER S, WALTER H, ANGEL-BERGER P, KOCH G, POZZERA A, DEECKE L, PoDREKA I, BRÜCKE T (1995) ß-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. J Neural Transm [Gen Sect] 100: 247–256
PISANI F, SPINA E, OTFRI G (1999) Antidepressant drugs and seizure susceptibility: from in vitro data to clinical practice. Epilepsia 40: 548–556
POLLACK M, ZANINELLI R, GODDARD A et al. (2001) Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 62: 350–357
PRAGER G, STOLLMAIER W, PRAGER R et al. (1991) Sicherheit and Verträglichkeit von Fluvoxamin bei kardialen Risikopatienten. TW Neu-rol Psychiat 5: 548–562
PRICE J, WALLER PC, WOOD SM, MACKAY AV (1996) A comparison of the postmarketing safety of four selective serotonin reuptake inhibitors including the investigation of symptoms oc-curing on withdrawal. Br J Clin Pharmacol 42: 757–763
RAPAPORT MH, JuDD LL (1998) Minor depressive disorder and subsyndromal depressive symptoms: functional impairment and response to treatment. J Affect Disord 48: 227–232
RASMUSSEN BB, BROSEN K (2000) Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit 22: 143–154
RAVINDRAN AV, JUDGE R, HUNTER BN et al. (1997) A double-blind multicentre study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. J Clin Psychiatry 58: 112–118
RAVIZZA L, BARZEGA G, BELLINO S, BOGETTO F, MAINA G (1996) Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin re-uptake inhibitors (SSRIs). Psychopharmacol Bull 32: 167–173
REIMHERR FW, CHOUINARD G, COHN CK et al. (1990) Antidepressant efficacy of sertraline: a double-blind, placebo and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 5 [Suppl 12B]: 8–27
REZNIK I, SIROTA P (2000) Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics. J Clin Psychopharmacol 20: 410–416
RICKELS K, SCHWEIZER E, CLARY C, Fox I, WEISE C (1994) Nefazodone and imipramine in major depression: a placebo-controlled trial. Br J Psychiatry 164: 802–805
RICKELS K, ROBINSON DS, SCHWEIZER E, MARCUS RN, ROBERTS DL (1995) Nefazodone: aspects of efficacy. J Clin Psychiatry 56: 43–46
Roux P, KIBLEUR Y, FRACHON O et al. (1996) A double blind comparison of nefazodone and flouxetine in depressend patients [abstract no 3591. 149th Meeting of the American Psychiatric Association, New York
ROBERT P, MONTGOMERY SA (1995) Citalopram in doses of 20–60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacol 10: 20–60
ROBINSON DS, MARCUS RN, ARCHIBALD DG, HARDY SA (1996a) Therapeutic dose range of nefazodone in the treatment of major depression. J Clin Psychiatry 57: 6–9
ROBINSON DS, ROBERTS DL, SMITH JM, STRINGFELLOW JC, KAPLITA SB, SEMINARA JA, MARCUS RN (1996b) The safety profile of nefazodone. J Clin Psychiatry 57: 31–38
RoosE S, GLASSMAN A, ATHA E et al. (1994) Com-parative efficacy of selective serotonin re-uptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 151: 1735–1739
ROPERT R (1989) Fluoxetine versus clomipramine in major depressive disorders. Int Clin Psychopharmacol 4: 89–95
ROSENBERG C, DAMSBO N, FUGLUM E et al. (1994) Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre clinical study. Int Clin Psychopharmacol 9 [Suppl 1]: 41–48
Rom D, MATTES J, SHEEHAN KH, SHEEHAN DV (1990) A double-blind comparison of fluvoxamine, desipramine and placebo in outpatients with depression. Prog Neuropsychopharmacol Biol Psychiatry 14: 929–939
ROTHSCHILD A, SAMSON JA, BESETTE MP, CARTER-CAMPBELLJT (1993) Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry 54: 338–342
RUDOLPH RL, FEIGER AD (1999) A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 56: 171–181
SCHNEIDER LS, SMALL GW, HAMILTON SH, BYSTRITSKY A, NEMEROFF CB, MEYERS BS (1997) Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Fluoxetine Collaborative Study Group. Am J Geriatr Psychiatry 5: 97–196
SCHNYDER U, KOLLER-LIESER A (1996) A double-blind, multicentre study of paroxetine and maprotiline in major depression. Can J Psychiatry 41: 239–244
SCHOLL HP, KASPER S, DANOS P, HÖFLICH G, MÖLLER HJ (1994) Selektive Serotonin-Wiederaufnahmehemmer in der Behandlung von Zwangssymptomen im Rahmen schizophrener Erkrankungen. Nervenarzt 65: 478–481
SCHÖNE W, LUDWIG M (1993) A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol 13 [Suppl 2]: 34S–39S
SECHTER D, TROY S, Rtoux P (1996) A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients. 20th Congress of the International College of Neuropsychopharmacology, June 23–27, Melbourne
SECHTER D, TROY S, PATERNETTI S, BOYER P (1999) A double-blind comparison of sertraline and fluoxetine in the treatment of major depres-sive episode in outpatients. Eur Psychiatry 14: 41–48
SHARPLEY AL, WILLIAMSON DJ, ATTENBIJRROW ME, PEARSON G, SARGENT P, CoWEN PJ (1996) The effects of paroxetine and nefazodone on sleep: a placebo controlled trial. Psychopharmacology Berl 126: 50–54
SHAW DM, THOMAS DR, BRISCOE MH et al. (1986) A comparison of the antidepressant action of citalopram and amitriptyline. Br J Psychiatry 149: 515–517
SIMON GE, VONKORFF M, HEILIGENSTEIN JH, REVICKI DA, GROTHAUS L, KATON W, WAGNER EH (1996) Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 275: 1897–1902
SIMPSON K, NOBLE S (2000) Fluoxetine. A review of its use in women’s health. CNS Drugs 14: 301–328
SMERALDI E (1998) Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission. J Affect Disord 48: 47–56
SPENCER CM, WILDE MI (1998) Milnacipran. A review of its use in depression. Drugs 56: 405–427
SPROULE BA, NARANJO CA, BRENMER KE, HASSAN PC (1997) Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evicence. Clin Pharmacokinet 33: 454–471
SRINIVAS NR, SITYU WC, LEE J, GREENE DS, BARBHAI-YA RH (1997) Lack of effect of food on the steady state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects. Biopharm Drug Dispos 18: 585–593
STAHL SM (1998) Not so selective serotonin re-uptake inhibitors. J Clin Psychiatry 59: 343–344
STAHL SM (2000) Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol Psychiatry 48: 894–901
STARK P, HARIDSON CD (1985) A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry 46: 53–58
STEIN D, SPADACCINI E, HOLLANDER E (1995) Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int Clin Psychopharmacol 10: 11–18
STEINER M, STEINBERG S, STEWART D et al. (1995) Fluoxetine in the treatment of premenstrual syndrome. NEJM 332: 529–534
STOKES PE, HoLTZ A (1997) Fluoxetine tenth anniversary update: the progress continues. Clin Ther 19: 1135–1250
STOLLMAIER W, CIMANDER KF, WAGNER W (1989) Wirksamkeit und Verträglichkeit von Fluvox-amin (Fevarin) bei depressiven Syndromen in der Praxis. Nervenheilkunde 8: 247–252
STUPPÄCK C, GERETSEGGER C, WHITWORTH AB et al. (1994) A multicentre double-blind trial of paroxetin versus amitriptyline in depressed inpatients. J Clin Psychopharmacol 14: 241–246
SURI RA, ALTSHULER LL, RASGON NL, CALCAGNO JL et al. (2000) Efficacy and response time to sertraline versus fluoxetine in the treatment of unipolar major depressive disorder. J Clin Psychiatry 61: 942–946
SZABADI E (1992) Fluvoxamine withdrawal syndrome. Br J Psychiatry 160: 283–284
SZEGEDI A, WETZEL H, ANGERSBACH D et al. (1997) A double-blind study comparing paroxetine and maprotiline in depressed outpatients. Pharmacopsychiatry 30: 97–105
SZEGEDI A, ANGHELESCU I, WIESNER J, SCHIEGEL S, WEIGMANN H, HARTTER S, HIEMKE C, WETZEL H (1999) Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 32: 148–153
TEICHER MT, GLOD C, COLE JO (1990) Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 147: 207–210
THASE ME, BLOMGREN SL, BIRKETT MA, APTER JT, TEPNER RG (1997) Fluoxetine treatment of patients with major depressive disorder woh failed initial treatment with sertraline. J Clin Psychiatry 58: 16–21
THASE ME, LONDBORG P, CALABRESE J (1999a) Cita-lopram treatment of depressed patients discontinued from fluoxetine because of adverse events. ACNP, Acapulco, Mexico
THASE ME, LYDIARD B, FEIGHNER J (1999b) Citalo-pram treatment of fluoxetine nonresponders. APA, Washington, USA
THOMSEN PH (1997) Child and adolescent obsessive-compulsive disorder treated with citalopram: findings from an open trial of 23 cases. J Child Adolesc Psychopharmacol 7: 157–166
THOMPSON C (1999) Mirtazapine versus selective serotonin reuptake inhibitors. J Clin Psychiatry 60: 18–22; discussion 18–22
TIGNOL J (1993) A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression. J Clin Psychopharmacol 13 [Suppl 2]: 18S–22S
TILLER J, BOUWER C, BEHNKE K (1999) Mo clobemide and fluoxetine for panic disorder. Eur Arch Psychiatry Clin Neurosci 249 [Suppl 1]: S7—S10
TIMMERMAN I, DE BEURS P, TAN BK et al. (1987) A double-blind comparative clinical trial of citalopram vs maprotiline in hospitalized depressed patients. Int Clin Psychopharmacol 2: 239–253
TOLLEFSON GD, SAYLER ME (1996) Course of psychomotor agitation during pharmacotherapy of depression: analysis from double-blind controlled trials with fluoxetine. Depress Anxiety 4: 294–311
TOURIGNY-RIVARD MF (1997)Pharmacotherapy of affective disdorders in old age.Can J Psychiatry 42 [Suppl 1]:10S–18S
VAN MOFFAERT M, PREGALDIEN JL, VON FRENCKELL R et al. (1994) A double blind comparison of nefazodone and imipramine in the treatment of depressed patients. New Trends Exp Clin Psychiatry 10: 85–87
VAN MOFFAERT M, BARTHOLOME F, COSYNS P et al. (1995) A controlled comparison of sertraline and fluoxetine in acute and continuation treatment of major depression. Hum Psychopharmacol 10: 393–405
VAN VLIET I, DEN BOER JA, WESTENBERG HGM (1994) Psychopharmacological treatment of social phobia: a double-blind placebo controlled study with fluvoxamine. Psychopharmacology 115: 128–131
VANELLE J, ATTAR-LEVY D, POIRIER MF et al. (1997) Controlled efficacy study of fluoxetine in dysthymia. Br J Psychiatry 170: 345–350
VoLz HP, LAUX P (2000) Potential treatment for subthreshold and mild depression: a comparison of St. John’s wort extracts and fluoxetine. Compr Psychiatry 41: 133–137
WADE AG, LEPOLA U, KOPONEN HJ et al. (1997) The effect of citalopram in panic disorder. Br J Psychiatry 170: 549–553
WADE A, LEMMING OM, HEDEGAARD KB (2002) Es-citalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 17: 95–102
WAGNER W, PLEKKENPOL B, GRAY TE et al. (1992) Review of fluvoxamine safety database. Drugs 43 [Suppl 21: 48–54
WAGNER W, PLEKKENPOL B, GREY TE, VLASKMAP H, ESSERS H (1993) Safety database on fluvoxamine: analysis and report. Pharmacopsychiatry 26 [Suppl]: 10–16
WAGNER W, ZABORNY BA, GRAY TE (1994) Fluvox-amine. A review of its safety profile in world-wide studies. Int Clin Psychopharmacol 9: 223–227
WALDINGER MD, HENGEVELD MW, ZWINDERMAN AH et al. (1998) Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine and sertraline. J Clin Psychopharmacol 18: 274–281
WALDINGER M, ZWINDERMAN A, OLIVIER B (2000) SSRIs and ejaculation: a double-blind, randomized, comparative fixed-dose study with paroxetine and citalopram. American Psychiatric Association Annual Meeting, Chicago
WARE M (1997) Fluvoxamine: a review of the controlled trials in depression. J Clin Psychiatry 58 [Suppl 51: 15–23
WASLICK BD, WALSH BT, GREENHILL LL, EILENBERG M, CAPASSO L, LIEBER D (1999) Open trial of fluoxetine in children and adolescents with dysthymic disorder or double depression. J Affect Disord 56: 227–236
WEBER H, DITrMANN RW (1997) Therapeutische Wirksamkeit von Fluoxetin in der Routinepraxis. Psychopharmakotherapie 4 [Suppl 51: 23–27
WESTENBERG HG (1996) Developments in the drug treatment of panic disorder: what is the place of the selective serotonin reuptake inhibitors? J Affect Disord 40: 85–93
WIKANDER I, SUNDBLAD C, ANDERSCH B et al. (1998), Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol 18: 390–398
WILDE MI, BENFIELD P (1998) Fluoxetine. A pharamcoeconomic review of its use in depression. Pharmacoeconomics 13: 543–561
WILDE MI, PLOSKER GL, BENFIELD P (1993) Fluvox-amine. An update review of its pharamacology, and therapeutic use in depressive illness. Drugs 46: 895–924
WILLEIT M, PRASCHAK-RIEDER N, NEUMEISTER A, PIRKER W, VITOUCH O, ASENBAUM S, BRÜCKE T, TAUSCHER J, KASPER S (2000) (1230-j3-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug free depressed patients with seasonal affective disorder. Biol Psychiatry 47: 482–489
WILSON SJ, BELL C, COUPLAND NJ, NUTT DJ (2000) Sleep changes during long-term treatment of depression with fluvoxamine — a home-based study. Psychopharmacology (Berl) 149: 360–365
WISNER KL, PEREL JM, FINDLING RL (1996) Anti-depressant treatment during breast-feeding(see comments). Am J Psychiatry 153: 1132–1137
WISNER KL, GELENBERG AJ, LEONARD H, ZARIN D, FRANK E (1999) Pharmacologie treatment of depression during pregnancy. JAMA 282: 1264–1269
ZAJECKA J, FAWCETT J, AMSTERDAM J, QUITKIN F et al. (1998) Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study. J Clin Psychopharmacol 18: 193–197
ZANARDI R, FRANCHINI L, GASPERINI M et al. (1996) Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry 153: 1631–1633
ZANARDI R, FRANCHINI L, SERRETTI A, PEREZ J, SMERAL-DI E (2000) Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. J Clin Psychia-try 61: 26–29
ZUCCARO P, PACIFICI R, ALTIERI I, AVENOSO A, PEILEGRINI M, SPINA E, PERUCCA E, PICHINI S (1998) Issues in methodology and applications for therapeutic drug monitoring of fluoxetine and norfluoxetine enantiomers. Ther Drug Monit 20: 20–24
Interaktionen(SSRI, DSA)
AHMED I, DAGINCOURT PG, MILLER LG, SHADER RI (1993) Possible interaction between fluoxetine and pimozide causing sinus bradycardia. Can J Psychiatry 38: 62–63
ALBERS U, REIS’r C, HELMESTE D, Vu R, TANG SW (1996) Paroxetine shifts imipramine metabolism. Psychiatry Res 59: 189–196
ALDERMAN CP (1999) Possible interaction between nefazodone and pravastatin. Ann Pharmacother 33: 871
ANGHELESCU I, SZEGEDI A, SCHLEGEL S, WEIGMANN H, HIEMKE C, WETZEL H (1998) Combiantion treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial. Eur Neuropsychopharmacol 8: 315–320
ARANOW AB, HUDSON JI, POPE. HG JR, GRADY TA, LAAGE TA, BEI.L IR, COLE JO (1989) Elevated antidepressant plasma levels after addition of fluoxetine. Am J Psychiatry 146: 911–913
ASHTON AK, WOLIN RE (1996) Nefazodone-induced carbamazepine toxicity. Am J Psychiatry 153: 733
AVENOSO A, SPINA E, CAMPO G, FACCIOLA G, FERLITO M, ZUCCARO P, PERUCCA E, CAPUTI AP (1997) Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications. Pharmacol Res 35: 335–339
AZAZ-LIVSHITS TL, DANENBERG HD (1997) Tachy-cardia, orthostatic hypotension and profound weakness due to concomitant use of fluoxetine and nifedipine. Pharmacopsychiatry 30: 274–275
BAETTIG D, BONDOLFI G, MONALDI S, AMEY M, BAU-MANN P (1993) Tricyclic antidepressant plasma levels after augmentation with citalopram: a case study. Eur J Clin Pharmacol 44: 403–405
BAKER B, DORIAN P, SANDOR P, SHAPIRO C, SCHELL C, MITCHELL J, IRVINE MJ (1997) Electrocardio-graphic effects of fluoxetine and doxepin in patients with major depressive disorder. J Clin Psychopharmacol 17: 15–21
BARBHAIYA RH, SHUKLA HA, KROBOTH PD, GREENE DS (1995) Coadministration of nefazodone and henzodiazepines. II. A pharmacokinetic interaction study with triazolam. J Clin Psychopharmacol 15: 320–326
BARBHAIYA RH, SHUKLA UA, GREENE DS, BREUL HP, MIDHA KK (1996) Investigation of pharmacokinetic and pharmacodynamie interactions after coadministration of nefazodone and haloperidol. J Clin Psychopharmacol 16: 26–34
BAUMANN P (1996) Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 31: 444–469
BAUMANN P, NIL R, SOUCHE A, MONTALDI S, BAEITIG D, LAMBERT S, UEHI.INGER C, KASAS A, AMEY M, JONZIER-PEREY M (1996) A double-blind, place-bo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 16: 307–314
BENDER S, EAP CB (1998) Very high cytochrome P4501A2 activity and nonresponse to clozapine. Arch Gen Psychiatry 55: 1048–1050
BENAZZI F (1999) Venlafaxine-fluoxetine interac-tion. J Clin Psychopharmacol 19: 96–98
BERGSTROM RF, PEYTON AL, LEMBERGER L (1992) Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 51: 239–248
BERTSCHY G, VANDEL S, VANDEI. B, ALLERS G, VOI.MAT R (1991) Fluvoxamine-tricyclic antidepressant interaction. An accidental finding. Eur J Clin Pharmacol 40: 119–120
BERTSCHY G, EAP CB, POWELL K, BAUMANN K (1996) Fluoxetine addition to methadone in addicts: pharmacokinetic aspects. Ther Drug Monit 18: 570–572
BONDOLFI G, CHATEMS C, ROCHAT B, BERTSCHY G, BAUMANN P (1996) Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Psychopharmacology 128: 421–425
BONDOLFI G, LISSNER C, KOSEI. M EAP CB, BAUMANN P (2000) Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences. Int J Neuropharmacol 3: 55–60
BOSI WICK JM, BROWN TM (1996) A toxic reaction from combining fluoxetine and phentermine. J Clin Psychopharmacol 16: 189–190
BREMEN K (1998)Differences in interactions of SSRIs. Int Clin Psychopharmacol 13 [Suppl 5]: S45—S47
BUCHANAN RW, KIRKPATRICK B, BRYANT N, BALL P, BREIER A (1996) Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am J Psychiatry 153: 1625–1627
BLAIR RASMUSSEN B, BRQ SEN K (2000) Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit 22: 143–154
CADIEUX RJ (1999) Antidepressant drug interactions in the elderly. Understanding the P-450 system is half the battle in reducing risks. Postgrad Med 106: 231–232
CALLAGHAN JT, BERGSTROM RF, PTAK ER, BEASLEY CM (1999) Olanzapine. Pharmacokinetic and pharmacodynamie profile. Clin Pharmacokinet 37: 177–193
CARRILLO JA, RASMOS SI, HERRAIZ AG, LLERENA A, AGUNDEZ JA, BERECZ R, DURAN M, BENPPEZ J (1999) Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. J Clin Psychopharmacol 19: 494–399
CENTORRINO F, BALDESSARINI RJ, FRANKENBURG FR, KANDO J, VOLPICELLI SA, FLoou JG (1996) Serum levels of clozapine and norclozapine in patients treated with selective serotonin re-uptake inhibitors. Am J Psychiatry 153: 820–822
CHAMBOST M, LIRON L, PEILLON D, COMBE C (2000) Serotonin syndrome during fluoxetine poisoning in a patient taking moclobemide. Can J Anaesth 47: 246–250
CHONG, SA, TAN CH, LEE HS (1997) Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: two case reports. J Clin Psychopharmacol 17: 6869
COUINARD G, LEKO-SINGH K, TEBOUL E (1999) Me-tabolism of anxiolytics and hypnotics: benzo-diazepines, buspirone, zopiclone, and zolpidem. Cell Mol Neurobiol 19: 533–552
CONUS P, BONDOLFI G, EAP CB, MACCIARDI F, BAU-MANN P (1996) Pharmacokinetic fluvoxamineclomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient. Pharmacopsychiatry 29: 108–110
CORSINI A, BELLOSTA S, BAETTA R, FUMAGALLI R, PAOLETrI R, BERNINI F (1999) New insights into the pharmacodynamie and pharmacokinetic properties of statins. Pharmacol Ther 84: 413–428
DAMKIER P, FL NSEN LL, BROSEN K (1999) Effect of fluvoxamine on the pharmacokinetics of quinidine. Eur J Clin Pharmacol 55: 451–456
DANIEL WA, SYREK M, HADUCH A, WOJCIKOWSKI J (1999) The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. Exp Toxicol Pathol 51: 309–314
DAUBRESSE JC, KOLANOWSKI J, KRZENTOWSKI G, KUTNOWSKI M, SCHEEN A, VAN GAAL L (1996) Useful-ness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study. Obes Res 4: 391–396
DEMARIA PA JR, SEROTA RD (1999) A therapeutic use of the methadone fluvoxamine drug interaction. J Addict Dis 18: 5–12
DEVANE CL, MARKOWITZ JS, HARDESTY SJ, MUNDY S, GILL HS (1997) Fluvoxamine-induced theophylline toxicity. Am J Psychiatry 154: 1317–1318
DENT LA, ORROCK MW (1997) Warfarin-fluoxetine and diazepam-fluoxetine interaction. Phannacotherapy 17: 170–172
DINGEMANSE J,WALLNOFER A, GIESCHKE R, GUENTERT T, AMREIN R (1998) Pharamcokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the „serotonin syndrome“. Clin Pharmacol Ther 63: 403–413
DOCKENS RC, GREENE DS, BARBHAIYA RH (1996) Assessment of pharmacokinetic and pharmacodynamie drug interactions between nefazodone and digoxin in healthy male volunteers. J Clin Pharmacol 36: 160–167
DRAKE WM, GORDON GD (1994) Heart block in a patient on propranolol and fluoxetine. Lancet 343: 425–425
DRESSER GK, SPENCE JD, BAILEY DG (2000) Pharma-cokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38: 4157
DRICI MD, WANG WX, Liu XK, WOOSLEY RL, FLOCK-HART DA (1998) Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. J Clin Psychopharmacol 18: 477–481
DUNCAN D, SAYAL K, MCCONNELL H, TAYLOR D (1998) Antidepressant interactions with warfarin. int J Psychopharmacol 13: 87–94
DURSUN SM, MATI IEW VM, REVELEY MA (1993) Toxic serotonin syndrome after fluoxetine plus carbamazepine. Lancet 342: 442–443
EBERT D, ALBERT R, MAY A, STOSIEK I, KASCHKA W (1995) Combined SSRI-RIMA treatment in refractory depression safety data and efficacy. Psychopharmacology 119: 342–344
ECKERT A, REIFF J, MÜLLER WE (1998) Arzneimittel-interaktionen mit Antidepressiva. Psychopharmakotherapie 5: 8–18
ELKO CJ, BURGESS JL, ROBERTSON WO (1998) Zolpi-dem-associated hallucinations and serotonin reuptake inhibition: a possible interaction. J Toxicol Clin Toxicol 36: 195–203
ERESHEFSKY L, RIESENMAN C, LAM YW (1995) Anti-depressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Clin Pharmacokinet 29 [Suppl 1]: 10–18
FITZSIMMONS ME, COLLINS JM (1997) Selective bio-transformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab Dispos 25: 256–266
FITZSIMMONS ME, METHA S (1999) Serotonin syndrome caused by overdose with paroxetine and moclobemide. J Accid Emerg Med 16: 293–295
GOFF DC, MIDHA KK, BROTMAN AW, WAITES M, BAL-DESSARINI RJ (1991) Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. Anti Psychiatry 146: 790–792
GOFF DC,MIDHA KK, SARID-SEGAL O, HUBBARD JW, AMIGO E (1995) A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology (Berl) 117: 417–423
GOODNICK PJ (1994) Pharmacokinetic optimisation of therapy with newer antidepressants. Clin Pharmacokinet 27: 307–330
GREENE S, BARBHAIYA RH (1997) Clinical pharmacokinetics of nefazodone. Clin Pharmacokinet 33: 260–275
GREENE S, SALAZAR DE, DOCKENS RC, KROBOTII P, BARBHAIYA RII (1995) Coadministration of nefazodone and benzodiazepines. III. A pharmacokinetic interaction study with alprazolam. J Clin Psychopharmacol 15: 399–408
GREENBLATT DJ, VON MOLTKE LL, HARMATZ JS, SHAD ER RI (1998) Drug interactions with newer antidepressants: role of human cytochromes P450. J Clin Psychiatry 59 [Suppl 151: 19–27
GRIMSLEY SR, JANN, MW, CARTER JG,D’MELLO AP,D’SoUZA MJ (1991) Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther 50: 10–15
GRTNSHPOON A, BERG Y, MOZES T, MESTER R, WEIZ-MAN A (1993) Seizures induced by combined levomepromazine-fluvoxamine treatment. Int Clin Psychopharmacol 8: 61–62
HÄRTTER S, GRÖZINGER M, WEIGMANN H, RÖSCHKP. J, HIEMKE C (2000) Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clin Pharmacol Ther 67: 1–6
HAPPEN E, VANDEL P, BROLY F, VANDEL S, SECIITER D, BIZOUARD P, BECHTEL PR (1999) Citalopram: an interaction study with clornipramine in a patient heterozygous for CYP2D6 genotype. Pharmacopsychiatry 32: 232–234
HARVEY AT, BURKE M (1995) Comment on: the serotonin syndrome associated with paroxetMe, an over-the-counter cold remedy, and vascular disease. Am J Emerg Med 13: 605–607
HARVEY AT, PRESKORN SH (1996) Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors, part I. J Clin Psychopharmacol 16: 273–285
HEGERL U, MÖLLER HJ (1999) Pharmakotherapie der Altersdepression. Nervenarzt 71: 1–8
HEGERL U,BoerLENDER R, GALLINAT J, Kuss HJ, ACKENHEIL M, MOLLER HJ (1998) The serotonin syndrome scale: first results on validity. Eur Arch Psychiatry’ Clin Neurosci 248: 96–103
HEINONEN EH,MYLLYLA V (1998) Safety of selegiline (deprenyl) in the treatment of Parkinson’s disease. Drug Saf 19: 11–22
HEMERYCK A, DE VRIENDT C, BELPAIRE FM (1999) Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes. Eur J Clin Pharmacol 54: 947–951
HIEMKE C (1997) Interaktionen and Metabolismus neuerer Antidepressiva. Munch Med Wochen-sehr 139: 484 186
HIEMKE C, HÄRTTER S (2000) Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 85: 11–28
HIEMKE C, WEIGMANN H, HÄRTTER S, DAIIMEN N, WE‘I’ZEL H, MOLLER H (1994) Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 14: 279–281
HILTON SE,MARADIT H,MÖLLER HJ (1997) Serotonin syndrome and drug combinations: focus on MAOI and RIMA. Eur Arch Psychiatry Clin Neurosci 247: 113–119
JACOBSON RH,WANG P,GLUECK CJ (1997) Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone. JAMA 277: 296–297
JEFEERSONJW (1998) Drug interactions-friend or foe? J Clin Psychiatry 59 [Suppl 4]: 37–47
JEPPESEN U, GRAM I.F, VISTISEN K, LOFT S, POULSEN HE, BROSEN K (1996) Dose-dependent inhibition of CYPIA2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 51: 73–78
JERLING M, LINDSTROM L, BONDESSON U, BERTILSSON L (1994) Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 16: 368–374
JOFEE RT, BANISH D (1994) Combined SSRI-moclobemide treatment of psychiatric illness. J Clin Psychiatry 55: 24–25
KESAVAN S, SOBALA GM (1999) Serotonin syndrome with fluoxetine plus tramadol. J R Soc Med 92: 474–475
KETTER TA, CALLAHAN AM, POST R (1996) Nefazodone relief of alprazolam interdose dysphoria: a potential therapeutic benefit of 3A3/4 inhibition. J Clin Psychiatry 57: 307
KÖHLER D, HARTTER S, FUCHS K, SIEGHART W, HIEMKE C (1997) CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication. Pharmacogenetics 7: 453–461
KÖNIG F, HAFELE M, HAUGER B, LOBLE M, WOSSNER S, WOLFERSDORE M (1996) Bradycarclia after beginning therapy with metoprolol and paroxetine. Psychiatr Prax 23: 244–245
KUDO S, TSHIZAKI T (1999) Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet 37: 435–456
KLIRTZ DI,, BERGSTROM RF, GOLDBERG MJ, CERIMELE BJ (1997) The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Pharmacol Ther 62: 145–156
LANE RM (1996) Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int Clin sychopharmacol 11 [Suppl 51: 31–61
LANE R, BALDWIN D (1997) Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol 17: 208–221
LANTZ MS, BUCHALTER EN,GIAMBANCO V (1998)Serotonin syndrome following the administra-tion of tramadol with paroxetine. Int J Geriatr Psychiatry 13: 343–345
LAROUDIE C, SALAZAR DE, COSSON JP, CHEUVART B, ISTIN B, GIERAULT J, INGRAND I, DECOURT JP (2000) arbamazepine-nefazodone interaction in healthy subjects. J Clin Psychopharmacol 20: 46–53
LARSEN JT, HANSEN LL, SPIGSET O, BRQSEN K (1999) Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo. Fur J Clin Pharmacol 55: 375–382
LEE DO, LEE CD (1999) Serotonin syndrome in a child associated with erythromycin and sertraline. Pharmacotherapy 19: 894–896
LEINONEN E, LEPOLA U, KOPONEN H (1996a) Substi-tuting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases. Pharmacopsychiatry 29: 156–158
LEINONEN E, LEPOLA U, KOPONEN H, KINNUNEN I (1996b) The effect of age and concomitant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenantioselective method. Ther Drug Monit 18: 111–117
LEUCHT S, HACKL HJ, STEIMER W, ANGERSBACH D, ZIMMER R (2000) Effect of adjunctive paroxetMe on serum levels and side-effects of tricyclic antidepressant in depressive inpatients. Psychopharmacology 147: 378–383
LEVITT AJ, JOFFE RT, KAMIL R, MCINTYRE R (1999) Do depressed subjects who have failed both fluoxetine and a tricyclic antidepressant respond to the combination? J Clin Psychiatry 60: 613–616
LINNOILA M, STAPLETON JM, GEORGE DT, LANE E, ECKARDT MJ (1993) Effects of fluvoxamine alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in healthy volunteers. J Clin Psychopharmacol 13: 175–180
LURCOTT G (1998) The effects of the genetic absence and inhibition of CYP2D6 on the metabolism of codeine and ist derivates, hydrocodone and oxycodone. Anesth Prog 45: 154–156
MASON BJ, BLACKBURN KH (1997) Possible serotonin syndrome associated with tramadol and sertraline coadministration. Ann Pharmacother 31: 175–177
MATHEW NT, TITJEN GE, DICKER C (1996) Serotonin syndrome complicating migraine pharmacotherapy. Cephalalgia 16: 323–327
MENZNER A, WEILEMANN LS (1999) Akute Medikamenten-Vergiftungen - neue Ergebnisse and Trends (1996–1998). Intensivmed 36: 1996–1998
MESSINA FS (1993) Fluoxetine: adverse effects and drug-drug interactions. J Toxicol Clin Toxicol 31: 603–630
MISHRA A, FRIEDMANN HS, SINHA AK (1999) The effects of erythromycin on the electrocardiogram. Chest 115: 983–986
MOLTKE VON LL,GREENBLATT DJ,COURT MH, DIAAN SX, HARMATZ JS, SHADER RI (1995) Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 15: 125–131
MOLTKE VON LL, GREENBLATT DJ, DUAN SX, SCHMIDER J, WRIGHT CE, HARMATZ JS, SHADER RI (1997) Human cytochromes mediating N-demethylation of fluoxetine in vitro. Psychopharmacology Berl 132: 402–407
MOLTKE VON LL, GREENBLATT DJ, GRANDA BW, GRASSI JM, SCHMIDER J, HARMATZ JS, SHADER RI (1999) Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450–3A4 inhibitory actions. Psychopharmacology 145: 450–3
MULY EC, MCDONALD W, STEFFENS D, BOOK S (1993) Serotonin syndrome produced by a combination of fluoxetine and lithium. Am J Psychiatry 150: 1565
NARANJO CA, SPROULE BA, KNOKE DM (1999) Met-abolic interactions of central nervous system medications and selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 14 [Suppl 2]: S35–S47
OHMAN R, SPIGSET O (1993) Serotonin syndrome induced by fluvoxamine-lithium interaction. Pharmacopsychiatry 26: 263–264
OLESON OV, LINNET K (2000) Fluvoxatnine-clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism. J Clin Psychopharmacol 20:35–42
OLYAEI AJ, DEM rios AM, NORMAN DJ, BENNETT WM (1998) Interaction between tacrolimus and nefazodone in a stable transplant recipient. Pharmacotherapy 18: 1356–1359
OWEN JR, NEMEROFF CB (1998) New antidepressants and the cytochrome P450 system: focus onvenlafaxine, nefazodone, and mirtazapine. Depress Anxiety 7 [Suppl 1]: 24–32
PALOP V, JIMENEZ MJ, CATALAN C, MARTINEZ-MIR I (1999) Acute dystonia associated with fluvox-amine-metoclopramide. Ann Pharmacother 33: 382
PERUCCA E, GATTI G, CIPOLLA G, SPINA E, BAREL S, SOBACK S, GIPS M, BIALER M (1994) Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 56: 471–476
PISANI F, SPINA E, OTERI G (1999) Antidepressant drugs and seizure susceptibility: from in vitro data to clinical practice. Epilepisa 40 [Suppl 101: S48—S56
POLLAK PT, SKETRIS IS, MACKENHZIE SL, HEWLETT TJ (1995) Delirium probably induced by clarithromycin in a patients receiving fluoxetine. Ann Pharmacother 29: 486–488
PORENTA G (2000) Kardiovaskuläre Nebenwirkungen von Psychopharmaka. In: KÖNIG F, KASCHKA WP (Hrsg) Interaktionen und Wirkmechanismen ausgewählter Psychopharmaka. Thieme, Stuttgart, S 89–103
PRESKORN SH, BAKER B (1997) Fatility associated with combined fluoxetine-amitriptyline therapy. JAMA 277: 1682
PRISKORN M, LARSEN F, SEGONZAC A, MOULIN M (1997) Pharmacokinetic interaction study of citalopramin and cimetidine in healthy subjects. Fur J Clin Pharmacol 52: 241–242
REILLY JG, AYIS SA, FERRIER IN, JONES SJ, THOMAS SH (2000) QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 355: 1048–1052
RICH JM,NJO L,ROBERTS KW,SMITH KP (1998) Unusual hypotension and bradycardia in a patient receiving fenfluramine, phentermine, and fluoxetine. Anesthesiology 88: 529–531
RICIIELSON E (1998) Pharmacokinetic interactions of antidepressants. J Clin Psychity 59 [Suppl 10]: 22–26
RICKELS K,SCIIWEIZER E,CASE WG,DEMARTININS N, GREENBLATT DJ,MANDOS LA,GARCIA-ESPANA FG (1998) Nefaozdone in major depression: adjunctive benzodiazepine therapy and tolerability. J Clin Psychopharmacol 18: 145–153
ROTHSCHILD AJ, SAMSON JA, BESSE I I L MP, CARTER-CAMPBELLJT (1993) Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry 54: 338–342
SALOKANGAS RK, SAARIJARVI S, TAIMINEN T, KALLIONIEMI H, LEHTO H, NIEMI H, TUOUMINEN J, AHOLA V, SYVALAHTI E (1996) Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiatr Scand 94: 175–180
SEIFRITZ E, HOLSBOER-TRACHSLER E, HEMMETER U, EAP CB, BAUMANN P (1994) Increased trimipramine plasma levels during fluvoxamine comedication. Eur Neuropsychopharmacol 4: 15–20
SHAD MU, PRESKORN SH (1998) Pharmacodynamic and pharmacokinetic factors in a case of neu-roleptic malignant syndrome. J Clin Psychopharmacol 18: 346–347
SHAD MU, PRESKORN SH (2000) Antidepressants. In: LEVY RH, THUMMEL KE, TRAGER WF, HANSTEN PD, EICHELBAUM M (eds) Metabolic drug interactions. Lippincott Williams & Wilkins, Philadelphia, pp 563–577
SHULMAN RW, OZDEMIR V (1997)Psychotropic medications and cytochrome P450 2D6:pharmacokinetic considerations in the elderly. Can J Psychiatry 42 [Suppl 1]: 4S–9S
SILVER H, KUSHNIR M, KAPLAN A (1996) Fluvoxam-ine augmentation in clozapine-resistant schizophrenia: an open pilot study. Biol Psychiatry 40: 671–674
SKOP BP, FINELSTEIN JA, MARETH TR, MAGOON MR, BROWN TM (1994) The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease. Am J Emerg Med 12: 642–644
SOBANSKI T, BAGLI M, LAUX G, RAO ML (1997) Serotonin syndrome after lithium add-on medication to paroxetine. Pharmacopsychiatry 30: 106–107
SPIGSET O (1998) Are adverse drug reactions attributed to fluvoxamine caused by concomitant intake of caffeine? Eur J Clin Pharmacol 54: 665–666
SPIGSET O, ADIELSSON G (1997) Combined serotonin syndrome and hyponatraemia caused by a citalopram-buspirone interaction. Int Clin Psychopharmacol 12: 61–63
SPINA E, PERUCCA E (1994) Newer and older antidepressants. CNS Drugs 2: 479–497
SPINA E, CAMPO GM, AVENOSO A, POLLICINO MA, CAN ITT AP (1992) Interaction between fluvoxamine and imipramine/desipramine in four patients. Ther Drug Monit 14: 194–196
SPINA E, POLLICINO AM, AVENOSO A, CAMPO GM, PERUCCA E, CAPUTI AP (1993) Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 15: 243–246
SPROULE BA, NARANJO CA, BRENMER KE, HASSAN PC (1997) Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet 33: 454–471
STERNBACH H (1991) The serotonin syndrome. Am J Psychiatry 148: 705–713
SZEGEDI A, WETZEL H, LEAL M, HARTTER S, HIEMKE C (1996) Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data. J Clin Psychiatry 57: 2.57–264
SZEGEDI A, ANGHELESCU I, WIESNER J, SCHLEGEL S, WEIGMANN H, NÄRTTE.g S, HIEMKE C, WETZEL H (1999) Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 32: 148–153
TAYLOR D (1995) Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination. Interactions and therapeutic uses. Br J Psychiatry 167: 575–580
TAYLOR D, ELLISON Z, EMENTON SHAW L, WICKHAM H, MURRAY R (1998) Co-administration of citalo-pram and clozapine: effect on plasma citalo-pram levels. Int Clin Psychopharmacol 13: 19–21
TAYLOR D, BODANI M, HUBBELING A, MURRAY R (1999) The effect of nefazodone on clozapine plasma concentrations. Int Clin Psychopharmacol 14: 185–187
TONINI M, DE PONTI F, DI Nucci A, CREMA F (1999) Review article: cardiac adverse effects of gastrointestinal prokinetics. Aliment Pharmacol Ther 13: 1585–1591
VANDEL S, BERTSCIIY G, BONIN B, NEZELOF S, FRANCOIS TH, VANDEL B, SECHTER D, BIZOUARD P (1992) Tricyclic antidepressant plasma levels after fluoxetine addition. Neuropsychobiology 25. 202–207
VANDEL S, BERTSCHY G, BAUMANN P, BOUQUET S, BONIN B, FRANCOIS T, SECHTER D, BIZOUARD P (1995) Fluvxoamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res 31: 347–353
VELLA JP, SAYEGH MH (1998) Interactions between cyclosporine and newer antidepressant medications. Am J Kidney Dis 31: 320–323
WALLEY T, PIRMOHAMED M, PROUDLOVE C, MAXWELL D (1993) Interaction of metoprolol and fluoxetine. Lancet 341: 967–968
WETZEL H, ANGHELESCO I, SZEGEDI A, WIESNER J, WEIGMANN H, HARI 1ER S, HIEMKE C (1998) Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 18: 2–9
WOODS DJ, COULTER DM, PILLANS P (1994) Interaction of phenytoin and fluoxetine. N Z Med J 107: 19
WOLFERSDORF M, BARG T, KÖNIG F, LEIBFAHRT M, GRUNEWALD I (1995) Paroxetine as antidepressant in combined antidepressant-neuroleptic therapy in delusional depression: observation of clinical use. Pharmacopsychiatry 28: 56–60
WRIGHT DH, LAKE KD, BRUHN PS, EMERYRW JR (1999) Nefazodone and cyclosporine drug-drug interaction. J Heart Lung Transplant 18: 913–915
YAP KB, Low ST(1999)Interaction of fluvoxamine with warfarin in an elderly woman.Singapore Med J 40: 480–482
Praktische Durchführung, allgemeine Behandlungsrichtlinien
ANDERSON I,TOMENSON B(1994) The efficacy of selective serotonin re-uptake inhibitors in depression:a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 8: 238–249
ANDERSON I, TOMENSON BM (1995) Treatment dis-continuation with selective serotonin re-uptake inhibitors compared with tricyclic re-uptake: a meta-analysis.Br Med J 310:1433–1438
ANSSEAU M, DARIMONT P, LECOQ A et al. (1994) Controlled comparison of nefazodone and amitriptyline in major depressive inpatients. Psychopharmacology 115: 254–260
ARANDA-MICHEL J, KOEHLER A, BEJARANO PA et al. (1999) Nefazodone-induced liver failure: report of three cases. Ann Intern Med 130: 285–288
BAUMANN P (1996) Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 6: 444–469
BLANKE J (1997) Antidepressive Medikation und Fahrtauglichkeit. Mönch Med Wochenschr 139: 478–480
BOERNER R, MOLLER H (2001) Aktuelle Standards der Pharmakotherapie von Angststörungen. Psychopharmakotherapie 8: 50–62
BOTTLENDER R, DOBMEIER P, MOLLER H (1998) Der Einfluss von selektiven Serotonin-Wiederaufnahmeinhibitoren auf die Blutgerinnung. Fortschr Neurol Psychiat 66: 32–35
CORNELIUS J, SALLOUM I, EHLER J et al. (1997) Fluox-etine in depressed alcoholics. A double-blind, placebo-controlled trial. Arch Gen Psychiatry 54: 700–705
DE JONGHE F, SwINKEIS J (1997) Selective serotonin reuptake inhibitors. Relevance of differences in their pharmacological and clinical profiles. CNS Drugs 7: 452–467
DIMMOCK P, WYATT K, JONES P et al. (2000) Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet 356: 1131–1136
EDWARDS J (1995) Drug choice in depression. Selective serotonin reuptake inhibitors or tricyclic antidepressants? CNS Drugs 4: 141–159
EDWARDS J, ANDERSON I (1999) Selection of serotonin reuptake inhibitors: a review. Drugs 57: 507–533
GLASSMAN A, RODRIGUEZ A, SHAPIRO P (1998) Use of antidepressants in patients with heart diseases. J Clin Psychiatry 59 [Suppl 10]: 16–21
GLEITER C, VOLZ H, MOLLER H (1999) Serotonin-Wiederaufnahmehemmer. Wissenschaftliche Verlagsgesellschaft, Stuttgart
GOLDSTEIN D, RAMPEY A, ENAS G et al. (1994) Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes 18: 129–135
GOLDSTEIN D, WILSON MG, THOMPSON VL (1995) Long-term fluoxetine treatment of bulimia nervosa. Br J Psychiatry 166: 660–666
GOLDSTEIN DJ, CORBIN LA, SUNDELL KL (1997) Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 89: 713–718
GREENBLATT D, VON MOLTKE L, HARMATZ J, SHADER R (1998) Drug interactions with newer antidepressants: role of human cytochromes P450.J Clin Psychiatry 59 [Suppl 15]: 19–27
GREIST J, JEFFERSON J, KOBAK K et al. (1995) Efficacy and tolerability of serotonin transport inhibitors on obsessive-compulsive disorder. Arch Gen Psychiatry 52: 53–60
HENDRICK V, FUKUCHI A, ALTSHULER L et al. (2001) Use of sertraline, paroxetine and fluvoxamine by nursing women. Br J Psychiatry 179: 163–166
HENRY J (1997) Toxicity of newer versus older antidepressants. Adv Psychiatr Treat 3: 41–45
HENRY J, ALEXANDER C, SENER E (1995) Relative mortality from overdose of antidepressants. Br Med J 310: 221–224
HINDMARCH I, ALFORD C, BARWELL F et al. (1992) Measuring the side-effects of psychotropics: the behavioural toxicity of antidepressants. J Psychopharmacol 6: 198–203
HOTOPF M, LEWIS G, NORMAND C (1996) Are SSRIS a cost-effective alternative to tricyclics? Br J Psychiatry 168: 404–409
HoTOPF M, HARDY R, LEWIS G (1997) Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. Br J Psychiatry 170: 120–127
JIMENEZ JLMENEZ F, MOLINA J (2000) Extrapyramidal symptoms associated with selective serotonin reuptake inhibitors. CNS Drugs 14: 367–379
Kocsls J, ZISHOOx S, DAVIDSON J et al. (1997) Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes. Am J Psychiatry 154: 390–395
KULIN N, PAS A, SAGE S et al. (1998) Preg-nancy outcome following maternal use of the new selective serotonin reuptake inhibitors. JAMA 279: 609–610
LANE R (1997) A critical review of selective serotonin reuptake inhibitor-related sexual dysfunction. Incidence, possible aetiology and implication for management. J Psychopharmacol 11: 72–82
LANE R, BALDWIN D (1997) Selective serotonin re-uptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol 17: 208–221
LANE R, BALDWIN D, PRESKORN S (1995) The SSRIs: advantages, disadvantages and differences. J Psychopharmacol 9 [Suppl]: 163–178
LAux G (2001) Cost-benefit analysis of newer versus older antidepressants. Pharmacopsychiatry 34: 1–5
LAUx G, HERBERG K (2001) Antidepressiva and Verkehrssicherheit. Editiones Roche, Basel
LECRUBIER Y, BAKKER A, DUNBAR G et al. (1997a) A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatr Scand 95: 145–152
LECRUBIER Y, JUDGE R, INVESTIGATORS a. t. C.P.P.S. (1997b) Long-term evaluation of paroxetine, clomipramine and placebo in panic disorders. Acta Psychiatr Scand 95: 153–160
LEJOYEUX M, ADES J, MOURAD I et al. (1996) Antide-pressant withdrawal syndrome: recognition, prevention and management. CNS Drugs 5: 278–292
MITCHELL P (1997) Drug interactions of clinical significance with selective serotonin reuptake inhibitors. Drug Safety 17: 390–102
MONTGOMERY SA, DEN BOER JA (2001) (eds) SSRIs in depression and anxiety. Wiley, London
MONTGOMERY S, JGC R, LYBY K et al. (1992) Dose response relationship of citalopram 20 mg citalopram 40 mg and placebo in the treatment of moderate and severe depression. Int Clin Psychopharmacol 6 [Suppl 51: 65–70
NULMAN J, ROVET J, STEWART DE et al. (1997) Neu-rodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 336: 258–262
OHBERG A, VUORI E, KLAUKKA T, LONNQVIST J (1998) Antidepressants and suicide mortality. J Affect Disord 50: 225–233
PHILIPP M, DELINI-STULA A, BAIER D, KOHNEN R, SCHOI.z H, LAUX G (1999) Assessment of sexual dysfunction in depressed patients and reporting attitudes in routine daily practice: results of the postmarketing observational studies with moclobemide, a reversible MAO-A inhibitor. Int J Psychiatry Clin Pract 3: 257–264
PHILIPP M, BALER D, KOHNEN R (2000) Vergleich der Wirkung von Moclobemid and SSRI auf sexuelle Funktionen bei depressiven Erwachsenen. Psychopharmakotherapie 7: 181–188
PICCINELLI M, PINT S, BELLANTUONO C, WILKINSON G (1995) Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br J Psychiatry 166: 424–443
POWER A (1998) Drug treatment of depression. Citalopram in overdose may result in serious morbidity and death. BMJ 316: 307–308
PRESKORN S (1995) Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 56 [Suppl1]: 12–21
PRESKORN S (1996) Clinical pharmacology of selective serotonin reuptake inhibitors. Professional Communications, Caddo PRESKORN 5 (1997) Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 32 [Suppl 1]: 1–21
REVICKI D,BROWN R,KELLER M et al. (1997) Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. J Clin Psychiatry 58: 47–58
RICHELSON E (1997) Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc 72: 835–847
RIEDEL M, MÜLLER N, MÜLLER WE, MÜLLER HJ (2000) Nefazodon, ein dual-serotonerges Antidepressivum. sychopharmakotherapie 7: 117–124
ROTHENHAUSLER H, HABERL C, EHRENTRAUT S et al. (2000) Suicide attempt by pure citalopram overdose causing long-lasting severe sinus bradycardia, hypotension and syncopes: successful therapy with a temporary pacemaker. Pharmacopsychiatry 33: 150–152
SALZMAN C, SCHNEIDER L, ALEXOPOULOS S (1995) Pharmacological treatment of depression in late life. In: BLoos F, KUPFER D (eds) Psycho-pharmacology: the fourth generation of progress. Raven Press, New York
SALZMAN C, SATLIN A, BURROWS W (1999) Geriatric psychopharmacology. In: SCHATZBERG A, NEMEROFF C (eds) Textbook of psychopharmacology. APP, Washington, pp 961–977
SCHREIBER W, WINKLER U, KRIEG J (1998) Sexuelle Dysfunktion and selektive Serotonin-Wiederaufnahmehemmer. rankenhauspsychiatrie 9: 8–11
SHAPIRO P, LESPERANCE F, FRASURE-SMITH N et al. (1999) An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT trial). Am Heart J 137: 1100–1106
SMERALDI F (1998) Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission. J Affect Disord 48: 47–56
SONG F, FREEMANTLE N, SHELDON T et al. (1993) Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. Br Med J 306: 683–687
STEIN D, SPADACCINI E, HOLLANDER E (1995) Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int Clin Psychopharmacol 10: 11–18
STEWART A (1998) Choosing an antidepressant: effectiveness based pharmacoeconomics. J Affect Disord 48: 125–133
SZEGEDI A,WETZEL H,ANGERSBACH D et al.(1997)Response to treatment in minor and major depression: results of a double-blind comparative study with paroxetine and maprotiline. j Affect Disord 45: 167–178
VAN AMERINGEN M, MANCLNI C, OAKMAN J, FARVOLDEN P (1999) Selective serotonin reuptake inhibitors in the treatment of social phobia. The emerging gold standard. CNS Drugs 11: 307–315
VAN DER KOLK B, DAEYEUSS D, MICHAELS M et al. (1994) Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry 55: 517–522
VAN LAAR MW, VAN WILLIGENBURG APP, VOLKERTS ER (1995) Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions, and daytime sleepiness in healthy adult and elderly subjects. J Clin Psychopharmacol 15: 30–40
VANELLE J, ATTAR-LEVY D, POIRIER M et al.(1997) Controlled efficacy study of fluoxetine in dysthymia. Br J Psychiatry 170: 345–350
WALSH BT, AGRAS WS, DEVLIN MJ et al. (2000) Fluoxetine for bulimia nervosa following poor response to psychotherapy. Am J Psychiatry 157: 1332–1334
WILLIAMS J, BARRETr J, OxMAN T et al. (2000) Treat-ment of dysthymia and minor depression in primary care. A randomized controlled trial in older adults. JAMA 284: 1519–1526
WISNER K, PEREL JM, FINDLING RL (1996) Antide-pressant treatment during breastfeeding. Am J Psychiatry 153: 1132–1137
Woovs S, Rizzo J (1997) Cost-effectiveness of antidepressant treatment reassessed. Br J Psychiatry 170: 257–263
YOSHIDA K, SMITH B, CRAGGS M, KUMAR C (1998) Fluoxetine in breast-milk and developmental outcome of breast-fed infants. Br J Psychiatry 172: 175–178
ZAJECKA J,TRACY K, MITCHELL S (1997) Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry 58:291–297
Exkurs: Meta-Analysen von Antidepressiva-Studien
AGUGLIA E, CASACCHIA M, CASSANO GB, FARAVELLI C, FERRARI G, GIORDANO P, PANCHERI P, RAVIZZA L, TRABUCCHI M, BOLINO F et al. (1993) Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol 8: 197–202
BEASLEY CMJ, DORNSEIF BE, BOSOMWORTH LC et al. (1991) Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ 303: 685–692 [published erratum appears in BMJ (1991) 303: 968]
BECH P (1993) Acute therapy of depression. J Clin Psychiatry 54 [Suppl]: 18–27
BECH P, CIALDELLA P (1992) Citalopram in depression-meta-analysis of intended and unintended effects. Int Clin sychopharmacol 61Suppl 51: 45–54
BENNIE EH, MULLIN JM, MARTINDALE JJ (1995) A double-blind multicenter trial comparing ser-traline and fluoxetine in outpatients with major depression. J Clin Psychiatry 56: 229–237
BOERNER RJ, MOLLER HJ (1999) The importance of new antidepressants in the treatment of anxiety/depressive disorders. Pharmacopsychiatry 32: 119–126
COHEN J (1977) Statistical power analysis for the behavioral sciences. Academic Press, Orlando DERSIMONIAN R, LAIRD N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188
DICKERSIN K, BERLIN JA (1992) Meta-analysis: state-of-the-Science. Epidemiol Rev 14: 154–176
DONOVAN S, MCGRADY H, POWNALL R et al. (1993) The efficacy and tolerability of dothiepin and three selective serotonin reuptake inhibitors in the treatment of major depression: a review of six double blind studies. Curr Ther Res 54: 275–289
DUNBAR GC (1995) Paroxetine in the elderly: a comparative meta-analysis against standard antidepressant pharmacotherapy. Pharmacology 51: 137–144
EGGER M, SMmI GD (1997) Meta-analysis. Potentials and promise. BMJ 315: 1371–1374
EGGER M, SMITH GD, PHILLIPS AN (1997) Meta-analysis: principles and procedures. BMJ 315: 1533–1537
FEINSTEIN AR (1995) Meta-analysis: statistical alchemie for the 21st century. J Clin Epidemiol 48: 71–79
GILBODY S, HOUSE A, SONG F, SHELDON T (1995) Misleading meta-analysis. Subject to many potential biases. BMJ 311: 1303–1304
GLAss GV, McGAW B, SMITH ML (1984) Meta-analysis in social research. Sage Publications, Beverly Hills GREISTJH, JEFFERSONJW (1998) Pharmacotherapy for obsessive-compulsive disorder. Br J Psychiatry [Suppl]: 64–70
HEDGES LV, OLKIN I (1985) Statistical methods for meta-analysis. Academic Press, Orlando
HEILIGENSTEIN JH, BEASLEY-CM J, Po IVIN JH (1993) Fluoxetine not associated with increased aggression in controlled clinical trials. Int Clin Psychopharmacol 8: 277–280
HIRSCIIFELD RMA (1999) Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. J Clin Psychiatry 60: 326–335
HOTOPF M, LEWIS G, NORMAND C (1996) Are SSRIs a cost-effective alternative to tricyclics? Br J Psychiatry 168: 404–409
KASPER S, FEGER J, MOLLER HJ (1992) Comparative efficacy of antidepressants. Drugs 43 [Suppl 21: 11–22
KIEV A, FEIGER A (1997) A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. J Clin Psychiatry 58: 146–152
KLAASSEN T, VERHEY FR, SNEIJDERS GH, ROZENDAAL N et al. (1995) Treatment of depression in Parkinson’s disease: a meta-analysis. J Neuropsychiatr Clin Neurosci 7: 281–286
MENTING JE, HONIG A, VERHEY FR et al. (1996) Selective serotonin reuptake inhibitors (SSRIs) in the treatment of elderly depressed patients: a qualitative analysis of the literature on their efficacy and side-effects. Int Clin Psychopharmacol 11: 165–175
MITTMANN N, HERRMANN N, EINARSON TR et al. (1997) The efficacy, safety and tolerability of antidepressants in late life depression: a meta-analysis. J Affect Disord 46: 191–217
MONTGOMERY SA, PEDERSEN V, TANGHOJ P et al. (1994) The optimal dosing regimen for citalopram — a meta-analysis of nine placebo-controlled studies. Int Clin Psychopharmacol 9 [Suppl 1]: 35–40
MONTGOMERY SA, DÜNNER DL, DUNBAR GC (1995) Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo. Eur Neuropsychopharmacol 5: 5–13
PANDE AC, SAYLER ME (1993) Adverse events and treatment discontinuations in fluoxetine clinical trials. Int Clin Psychopharmacol 8: 243–245
RAY JW, SHADISH WR (1996) How interchangeable are different estimators of effect size? J Consult Clin Psychol 64: 1316–1325
ROSENBERG WMC, DONALD A (1995) Evidence based medicine: an approach to clinical problem-solving. BMJ 310: 1122–1126
ROSENTHAI. R (1991) Meta-analytic procedures for social research. Sage, Beverly Hills SACKED’ D (1996) Evidence based medicine: what it is and what it isn’t. BMJ 312: 71–72
SACxETr D, OxMAN AD (1994) The Cochrane Collaboration handbook. Cochrane Collaboration, Oxford SACKETT D, ROSENBERG WMC (1995) The need for evidence-based medicine. J R Soc Med 88: 620–624
SINCLAIR JC, BRACKEN MB (1994) Clinically useful measures of effect in binary analyses of randomized trials. J Clin Epidemiol 47: 881–889
STASSEN HH, ANGST J, DELINI SA (1999) Fluoxetine versus moclobemide: cross-comparison between the time courses of improvement. Pharmacopsychiatry 32: 56–60
THURBER S, ENSIGN J, PUNNETT AF et al. (1995) A meta-analysis of antidepressant outcome studies that involved children and adolescents. J Clin Psychol 51: 340–345
TIGNOL J, STOKER MJ, DUNBAR GC (1992) Paroxetine in the treatment of melancholia and severe depression. Int Clin Psychopharmacol 7: 91–94
TOLLEFSON GD, HOLMAN SL (1994) How long to onset of antidepressant action: a meta-analysis of patients treated with fluoxetine or placebo. Int Clin Psychopharmacol 9: 245–250
TOLLEFSON GD, HOLMAN SL, SAYLER ME et al. (1994) Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. J Clin Psychiatry 55: 50–59
WALDINGER MD, HENGEVELD MW, ZWINDERMAN AH, OLIVIER B (1998) Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J Clin Psychopharmacol 18: 274–281
WERNICKE JF, SAYLER ME, KOKE SC et al. (1997) Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: the absence of an effect related to agitation and suicidal behavior. Depress Anxiety 6: 31–39
YusuF S, PETO R,LEwIS J et al. (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27: 335–371
Besprochene Meta-Analysen ANDERSON IM (1998) SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 7 [Suppl 1]: 11–17
ANDERSON IM, TOMENSON BM (1994) The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 8: 238–249
ANDERSON IM, TOMENSON BM (1995) Treatment discontinuation with selective serotonin re-uptake inhibitors compared with tricyclic antidepressants: a meta-analysis [see comments]. BMJ 310: 1433–1438
DAVIS JM, ZHENGYU W, JANICAK PG (1993) A quantitative analysis of clinical drug trials for the treatment of affective disorders. Psychopharmacol Bull 29: 175–181
EINARSON TR, ARIKIAN SR, CASCIANO J, DOYLE JJ (1999) Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clin Tiler 21: 296–308
GREENBERG RP, BORNSTEIN RF, ZBOROWSKI MJ, FISHER S et al. (1994) A meta-analysis of fluoxetine outcome in the treatment of depression. J New Ment Dis 182: 547–551
HOTOPF M, HARDY R, LEWIS G (1997) Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity [see comments]. BO Psychiatry 170: 120–127
KIRSCH I,SAPIRSTEIN G(1999)Listening to prozac but hearing placebo: a meta-analysis of antidepressant medication. Prevention &Treatment 1.American Psychological Association,5–16–99,Washington (http://www.journals.apa.org/prevention)
MOLLER HJ, HAUG G (1988). Secondary and meta-analysis of the efficacy of non-tricyclic antidepressants. Pharmacopsychiatry 21: 363–364
MÖLLER HJ, FUGER J, KASPER S (1994) Efficacy of new generation antidepressants: meta-analysis of imipramine-controlled studies. Pharmacopsychiatry 27: 215–223
MONTGOMERY SA, KASPER S (1995) Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Int Clin Psychopharmacol 9: 33–40
MONTGOMERY SA, HENRY J, MCDONALD G, DINAN T, LADER M, HINDMARCH I, CLARE A, NUrr D (1994)Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 9: 47–53 [published erratum appears in Int Clin Psychopharmacol (1994) 9: following 2961
SONG F, FREEMANTLE N, SHELDON TA et al. (1993) Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 306: 683–687
SRISURAPANONT M, BOONYANARUTHEE V (1997) Response and discontinuation rates of newer antidepressants: a meta-analysis of randomized controlled trials in treating depression. J Med Assoc Thai 81: 387–392
STEFFENS DC, KRISHNAN KR, HELMS MJ (1997) Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety 6: 10–18
WORKMAN EA, SHORT DD (1993) Atypical antidepressants versus imipramine in the treatment of major depression: a meta-analysis. J Clin Psychiatry 54: 5–12
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag/Wien
About this chapter
Cite this chapter
Laux, G. et al. (2002). Serotonin-selektive Antidepressiva(SSRI, DSA). In: Reiderer, P., Laux, G., Pöldinger, W. (eds) Neuro-Psychopharmaka Ein Therapie-Handbuch. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6150-0_4
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6150-0_4
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-83647-7
Online ISBN: 978-3-7091-6150-0
eBook Packages: Springer Book Archive